https://trial.medpath.com/news/ipsen-s-elafibranor-shows-promise-in-phase-ii-trial-for-primary-sclerosing-cholangitis 2025-04-24T10:36:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ipsen-s-elafibranor-shows-promise-in-phase-ii-trial-for-primary-sclerosing-cholangitis 2025-04-24T10:36:52+00:00 hourly 0.9 https://trial.medpath.com/news/cytovation-secures-6m-funding-to-advance-cy-101-cancer-therapy-into-phase-ii-trials 2025-04-24T10:36:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytovation-secures-6m-funding-to-advance-cy-101-cancer-therapy-into-phase-ii-trials 2025-04-24T10:36:48+00:00 hourly 0.9 https://trial.medpath.com/news/sun-pharma-and-moebius-medical-s-mm-ii-shows-promising-results-for-knee-osteoarthritis-in-phase-2b-trial 2025-04-24T10:36:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sun-pharma-and-moebius-medical-s-mm-ii-shows-promising-results-for-knee-osteoarthritis-in-phase-2b-trial 2025-04-24T10:36:47+00:00 hourly 0.9 https://trial.medpath.com/news/lotte-biologics-launches-dedicated-adc-manufacturing-facility-with-first-client-contract 2025-04-24T10:36:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lotte-biologics-launches-dedicated-adc-manufacturing-facility-with-first-client-contract 2025-04-24T10:36:21+00:00 hourly 0.9 https://trial.medpath.com/news/debiopharm-and-oncodesign-services-partner-to-advance-radiopharmaceutical-research-with-abylinktm-technology 2025-04-24T10:36:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/debiopharm-and-oncodesign-services-partner-to-advance-radiopharmaceutical-research-with-abylinktm-technology 2025-04-24T10:36:18+00:00 hourly 0.9 https://trial.medpath.com/news/turbine-unveils-first-ever-virtual-lab-platform-for-cell-simulations-in-drug-development 2025-04-24T10:17:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/turbine-unveils-first-ever-virtual-lab-platform-for-cell-simulations-in-drug-development 2025-04-24T10:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/archetype-therapeutics-to-present-ai-discovered-lung-cancer-drug-candidates-at-aacr-2025 2025-04-24T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/archetype-therapeutics-to-present-ai-discovered-lung-cancer-drug-candidates-at-aacr-2025 2025-04-24T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/antengene-to-showcase-six-innovative-cancer-therapies-at-aacr-and-asco-2025 2025-04-24T07:33:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/antengene-to-showcase-six-innovative-cancer-therapies-at-aacr-and-asco-2025 2025-04-24T07:33:23+00:00 hourly 0.9 https://trial.medpath.com/news/selution-slr-drug-eluting-balloon-shows-exceptional-3-year-patency-rates-in-peripheral-artery-disease-trials 2025-04-24T06:54:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/selution-slr-drug-eluting-balloon-shows-exceptional-3-year-patency-rates-in-peripheral-artery-disease-trials 2025-04-24T06:54:00+00:00 hourly 0.9 https://trial.medpath.com/news/sagemedic-s-3d-microtumor-assay-shows-promise-for-personalized-cancer-treatment-at-aacr-2025 2025-04-24T05:26:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sagemedic-s-3d-microtumor-assay-shows-promise-for-personalized-cancer-treatment-at-aacr-2025 2025-04-24T05:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/ono-pharma-to-present-positive-phase-2-data-for-tirabrutinib-in-pcnsl-and-ono-4578-in-rectal-cancer-at-asco-2025 2025-04-24T04:34:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ono-pharma-to-present-positive-phase-2-data-for-tirabrutinib-in-pcnsl-and-ono-4578-in-rectal-cancer-at-asco-2025 2025-04-24T04:34:01+00:00 hourly 0.9 https://trial.medpath.com/news/jak-inhibitor-selection-in-myelofibrosis-balancing-anemia-management-with-disease-control 2025-04-24T03:04:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jak-inhibitor-selection-in-myelofibrosis-balancing-anemia-management-with-disease-control 2025-04-24T03:04:12+00:00 hourly 0.9 https://trial.medpath.com/news/vanda-pharmaceuticals-battles-fda-over-gastroparesis-drug-hearing-delays 2025-04-24T02:34:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vanda-pharmaceuticals-battles-fda-over-gastroparesis-drug-hearing-delays 2025-04-24T02:34:13+00:00 hourly 0.9 https://trial.medpath.com/news/orphan-therapeutics-accelerator-pioneers-novel-funding-model-to-rescue-ultra-rare-disease-treatments 2025-04-24T02:03:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orphan-therapeutics-accelerator-pioneers-novel-funding-model-to-rescue-ultra-rare-disease-treatments 2025-04-24T02:03:40+00:00 hourly 0.9 https://trial.medpath.com/news/innovent-biologics-to-present-breakthrough-clinical-data-for-ibi363-pd-1-il-2-bispecific-antibody-at-asco-2025 2025-04-24T01:37:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innovent-biologics-to-present-breakthrough-clinical-data-for-ibi363-pd-1-il-2-bispecific-antibody-at-asco-2025 2025-04-24T01:37:02+00:00 hourly 0.9 https://trial.medpath.com/news/grail-to-present-real-world-data-from-100000-galleri-multi-cancer-detection-tests-at-aacr-2025 2025-04-24T01:36:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/grail-to-present-real-world-data-from-100000-galleri-multi-cancer-detection-tests-at-aacr-2025 2025-04-24T01:36:44+00:00 hourly 0.9 https://trial.medpath.com/news/leo-pharma-s-delgocitinib-cream-outperforms-alitretinoin-in-landmark-delta-force-trial-for-chronic-hand-eczema 2025-04-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leo-pharma-s-delgocitinib-cream-outperforms-alitretinoin-in-landmark-delta-force-trial-for-chronic-hand-eczema 2025-04-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-safety-analysis-reveals-increased-kidney-and-liver-toxicity-with-pembrolizumab-chemotherapy-combination-in-lung-cancer 2025-04-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-safety-analysis-reveals-increased-kidney-and-liver-toxicity-with-pembrolizumab-chemotherapy-combination-in-lung-cancer 2025-04-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/itm-and-alpha-9-oncology-partner-to-supply-rare-actinium-225-for-advanced-cancer-therapies 2025-04-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/itm-and-alpha-9-oncology-partner-to-supply-rare-actinium-225-for-advanced-cancer-therapies 2025-04-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/oncolytics-biotech-to-present-pelareorep-data-for-pancreatic-cancer-at-asco-2025 2025-04-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncolytics-biotech-to-present-pelareorep-data-for-pancreatic-cancer-at-asco-2025 2025-04-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/rezolute-secures-90-million-in-public-offering-to-advance-rare-disease-therapies 2025-04-23T23:04:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rezolute-secures-90-million-in-public-offering-to-advance-rare-disease-therapies 2025-04-23T23:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/long-term-follow-up-of-transform-trial-shows-sustained-benefits-of-liso-cel-car-t-cell-therapy-in-relapsed-lbcl 2025-04-23T22:37:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-term-follow-up-of-transform-trial-shows-sustained-benefits-of-liso-cel-car-t-cell-therapy-in-relapsed-lbcl 2025-04-23T22:37:30+00:00 hourly 0.9 https://trial.medpath.com/news/sickle-cell-disease-pipeline-shows-robust-growth-with-60-therapies-in-development-across-multiple-clinical-phases 2025-04-23T22:37:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sickle-cell-disease-pipeline-shows-robust-growth-with-60-therapies-in-development-across-multiple-clinical-phases 2025-04-23T22:37:00+00:00 hourly 0.9 https://trial.medpath.com/news/sakar-healthcare-secures-second-eu-marketing-authorization-for-colorectal-cancer-treatment 2025-04-23T22:36:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sakar-healthcare-secures-second-eu-marketing-authorization-for-colorectal-cancer-treatment 2025-04-23T22:36:10+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-to-showcase-breakthrough-cancer-therapies-at-asco-2025-with-over-60-presentations 2025-04-23T22:36:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-to-showcase-breakthrough-cancer-therapies-at-asco-2025-with-over-60-presentations 2025-04-23T22:36:09+00:00 hourly 0.9 https://trial.medpath.com/news/fda-warns-of-serious-side-effects-from-unapproved-topical-finasteride-hair-loss-treatments 2025-04-23T22:35:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-warns-of-serious-side-effects-from-unapproved-topical-finasteride-hair-loss-treatments 2025-04-23T22:35:16+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-and-tempus-ai-forge-200-million-oncology-ai-partnership-to-accelerate-cancer-drug-discovery 2025-04-23T20:36:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-and-tempus-ai-forge-200-million-oncology-ai-partnership-to-accelerate-cancer-drug-discovery 2025-04-23T20:36:57+00:00 hourly 0.9 https://trial.medpath.com/news/vertex-s-cystic-fibrosis-drug-alyftrek-receives-chmp-recommendation-for-eu-approval 2025-04-23T19:33:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vertex-s-cystic-fibrosis-drug-alyftrek-receives-chmp-recommendation-for-eu-approval 2025-04-23T19:33:51+00:00 hourly 0.9 https://trial.medpath.com/news/ema-grants-orphan-drug-designation-to-ab8939-for-acute-myeloid-leukemia-treatment 2025-04-23T19:33:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-grants-orphan-drug-designation-to-ab8939-for-acute-myeloid-leukemia-treatment 2025-04-23T19:33:50+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-fermentalg-and-givaudan-s-acid-stable-natural-blue-food-colorant 2025-04-23T19:33:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-fermentalg-and-givaudan-s-acid-stable-natural-blue-food-colorant 2025-04-23T19:33:47+00:00 hourly 0.9 https://trial.medpath.com/news/chimeric-therapeutics-raises-6-6-million-to-advance-novel-car-t-and-nk-cell-cancer-therapies 2025-04-23T19:33:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chimeric-therapeutics-raises-6-6-million-to-advance-novel-car-t-and-nk-cell-cancer-therapies 2025-04-23T19:33:33+00:00 hourly 0.9 https://trial.medpath.com/news/nanostics-begins-clinical-utility-study-for-ai-powered-prostate-cancer-test 2025-04-23T19:33:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanostics-begins-clinical-utility-study-for-ai-powered-prostate-cancer-test 2025-04-23T19:33:30+00:00 hourly 0.9 https://trial.medpath.com/news/biopoly-begins-fda-approved-clinical-trial-for-novel-knee-cartilage-implant 2025-04-23T19:33:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biopoly-begins-fda-approved-clinical-trial-for-novel-knee-cartilage-implant 2025-04-23T19:33:20+00:00 hourly 0.9 https://trial.medpath.com/news/new-research-reveals-how-vagus-nerve-encodes-immune-signals-during-inflammation 2025-04-23T19:04:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-research-reveals-how-vagus-nerve-encodes-immune-signals-during-inflammation 2025-04-23T19:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approved-apremilast-shows-dual-potential-for-alcohol-use-disorder-and-pain-management 2025-04-23T17:36:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approved-apremilast-shows-dual-potential-for-alcohol-use-disorder-and-pain-management 2025-04-23T17:36:01+00:00 hourly 0.9 https://trial.medpath.com/news/akeso-reports-positive-phase-3-results-for-ivonescimab-in-lung-cancer-building-on-recent-fda-approval-success 2025-04-23T17:05:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akeso-reports-positive-phase-3-results-for-ivonescimab-in-lung-cancer-building-on-recent-fda-approval-success 2025-04-23T17:05:49+00:00 hourly 0.9 https://trial.medpath.com/news/tempus-ai-astrazeneca-and-pathos-ai-form-200m-collaboration-to-build-oncology-foundation-model 2025-04-23T17:04:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tempus-ai-astrazeneca-and-pathos-ai-form-200m-collaboration-to-build-oncology-foundation-model 2025-04-23T17:04:40+00:00 hourly 0.9 https://trial.medpath.com/news/sk-bioscience-secures-landmark-victory-against-moderna-in-korean-mrna-patent-dispute 2025-04-23T16:46:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sk-bioscience-secures-landmark-victory-against-moderna-in-korean-mrna-patent-dispute 2025-04-23T16:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/baebies-secures-fda-breakthrough-designation-for-first-point-of-care-heparin-monitoring-test 2025-04-23T16:37:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/baebies-secures-fda-breakthrough-designation-for-first-point-of-care-heparin-monitoring-test 2025-04-23T16:37:09+00:00 hourly 0.9 https://trial.medpath.com/news/trustpoint-and-hexagon-secure-1-2m-navair-contract-to-develop-revolutionary-c-band-gnss-technology 2025-04-23T16:36:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trustpoint-and-hexagon-secure-1-2m-navair-contract-to-develop-revolutionary-c-band-gnss-technology 2025-04-23T16:36:58+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-t1d-invests-2-8-million-to-establish-joint-cardiorenal-center-of-excellence-for-type-1-diabetes-research 2025-04-23T16:36:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-t1d-invests-2-8-million-to-establish-joint-cardiorenal-center-of-excellence-for-type-1-diabetes-research 2025-04-23T16:36:49+00:00 hourly 0.9 https://trial.medpath.com/news/oncohost-s-plasma-proteomics-research-reveals-key-mechanisms-of-immunotherapy-resistance-in-nsclc 2025-04-23T16:36:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncohost-s-plasma-proteomics-research-reveals-key-mechanisms-of-immunotherapy-resistance-in-nsclc 2025-04-23T16:36:48+00:00 hourly 0.9 https://trial.medpath.com/news/ensysce-biosciences-secures-patent-for-novel-methadone-based-opioid-use-disorder-treatment 2025-04-23T16:36:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ensysce-biosciences-secures-patent-for-novel-methadone-based-opioid-use-disorder-treatment 2025-04-23T16:36:40+00:00 hourly 0.9 https://trial.medpath.com/news/cerevasc-s-eshunt-system-receives-fda-breakthrough-designation-for-pediatric-hydrocephalus-treatment 2025-04-23T16:36:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cerevasc-s-eshunt-system-receives-fda-breakthrough-designation-for-pediatric-hydrocephalus-treatment 2025-04-23T16:36:37+00:00 hourly 0.9 https://trial.medpath.com/news/tegoprazan-outperforms-standard-ppi-therapy-in-phase-3-gerd-trials 2025-04-23T16:36:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tegoprazan-outperforms-standard-ppi-therapy-in-phase-3-gerd-trials 2025-04-23T16:36:36+00:00 hourly 0.9 https://trial.medpath.com/news/boehringer-ingelheim-and-tessellate-bio-form-eur500m-partnership-to-target-alt-positive-cancers 2025-04-23T16:36:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boehringer-ingelheim-and-tessellate-bio-form-eur500m-partnership-to-target-alt-positive-cancers 2025-04-23T16:36:32+00:00 hourly 0.9 https://trial.medpath.com/news/novocure-s-phase-3-panova-3-trial-shows-promising-results-for-pancreatic-cancer-treatment 2025-04-23T16:36:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novocure-s-phase-3-panova-3-trial-shows-promising-results-for-pancreatic-cancer-treatment 2025-04-23T16:36:31+00:00 hourly 0.9 https://trial.medpath.com/news/peanut-allergy-treatment-market-poised-for-16-growth-as-new-therapies-enter-pipeline 2025-04-23T16:34:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/peanut-allergy-treatment-market-poised-for-16-growth-as-new-therapies-enter-pipeline 2025-04-23T16:34:56+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-status-to-mursla-bio-s-evoliver-test-for-early-liver-cancer-detection 2025-04-23T16:34:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-status-to-mursla-bio-s-evoliver-test-for-early-liver-cancer-detection 2025-04-23T16:34:53+00:00 hourly 0.9 https://trial.medpath.com/news/qiagen-unveils-advanced-cancer-genomic-profiling-tools-at-aacr-2025 2025-04-23T16:34:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qiagen-unveils-advanced-cancer-genomic-profiling-tools-at-aacr-2025 2025-04-23T16:34:44+00:00 hourly 0.9 https://trial.medpath.com/news/lakeshore-biopharma-launches-first-needle-free-rabies-vaccine-reconstitution-system-in-china 2025-04-23T16:34:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lakeshore-biopharma-launches-first-needle-free-rabies-vaccine-reconstitution-system-in-china 2025-04-23T16:34:17+00:00 hourly 0.9 https://trial.medpath.com/news/genentech-partners-with-repertoire-immune-medicines-in-765m-deal-for-autoimmune-disease-drug-discovery 2025-04-23T16:34:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genentech-partners-with-repertoire-immune-medicines-in-765m-deal-for-autoimmune-disease-drug-discovery 2025-04-23T16:34:11+00:00 hourly 0.9 https://trial.medpath.com/news/zealand-pharma-appoints-utpal-singh-as-cso-to-advance-peptide-therapeutics-for-obesity 2025-04-23T16:33:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zealand-pharma-appoints-utpal-singh-as-cso-to-advance-peptide-therapeutics-for-obesity 2025-04-23T16:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/sylvester-comprehensive-cancer-center-to-present-groundbreaking-research-at-asco-2025-annual-meeting 2025-04-23T16:04:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sylvester-comprehensive-cancer-center-to-present-groundbreaking-research-at-asco-2025-annual-meeting 2025-04-23T16:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/cardiff-oncology-secures-second-patent-for-onvansertib-in-bevacizumab-naive-mcrc-patients 2025-04-23T16:04:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cardiff-oncology-secures-second-patent-for-onvansertib-in-bevacizumab-naive-mcrc-patients 2025-04-23T16:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/merus-to-present-petosemtamab-combination-therapy-data-for-head-and-neck-cancer-at-2025-asco-meeting 2025-04-23T15:29:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merus-to-present-petosemtamab-combination-therapy-data-for-head-and-neck-cancer-at-2025-asco-meeting 2025-04-23T15:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/hawaii-advances-psychedelic-assisted-therapy-research-bill-with-4-million-funding-potential 2025-04-23T15:02:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hawaii-advances-psychedelic-assisted-therapy-research-bill-with-4-million-funding-potential 2025-04-23T15:02:25+00:00 hourly 0.9 https://trial.medpath.com/news/semaglutide-shows-promise-for-slowing-biological-aging-and-improving-cognition-in-hiv-patients 2025-04-23T14:53:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/semaglutide-shows-promise-for-slowing-biological-aging-and-improving-cognition-in-hiv-patients 2025-04-23T14:53:00+00:00 hourly 0.9 https://trial.medpath.com/news/cuban-drug-jusvinza-advances-through-phase-iii-trial-for-rheumatoid-arthritis-treatment 2025-04-23T11:04:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cuban-drug-jusvinza-advances-through-phase-iii-trial-for-rheumatoid-arthritis-treatment 2025-04-23T11:04:23+00:00 hourly 0.9 https://trial.medpath.com/news/remap-cap-trial-shows-hydrocortisone-reduces-mortality-in-severe-community-acquired-pneumonia 2025-04-23T11:00:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/remap-cap-trial-shows-hydrocortisone-reduces-mortality-in-severe-community-acquired-pneumonia 2025-04-23T11:00:14+00:00 hourly 0.9 https://trial.medpath.com/news/galapagos-reverses-course-on-company-split-appoints-henry-gosebruch-as-new-ceo 2025-04-23T10:36:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galapagos-reverses-course-on-company-split-appoints-henry-gosebruch-as-new-ceo 2025-04-23T10:36:10+00:00 hourly 0.9 https://trial.medpath.com/news/parabilis-medicines-demonstrates-first-ever-degradation-of-erg-in-prostate-cancer-models 2025-04-23T09:08:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/parabilis-medicines-demonstrates-first-ever-degradation-of-erg-in-prostate-cancer-models 2025-04-23T09:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/metavia-s-da-1241-shows-enhanced-hepatoprotective-effects-in-mash-combination-therapy 2025-04-23T08:32:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metavia-s-da-1241-shows-enhanced-hepatoprotective-effects-in-mash-combination-therapy 2025-04-23T08:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/calidi-biotherapeutics-appoints-eric-poma-as-new-ceo-to-advance-novel-cancer-virotherapy-platform 2025-04-23T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/calidi-biotherapeutics-appoints-eric-poma-as-new-ceo-to-advance-novel-cancer-virotherapy-platform 2025-04-23T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/zai-lab-to-present-phase-1-data-on-novel-dll3-targeted-adc-for-small-cell-lung-cancer-at-asco-2025 2025-04-23T07:56:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zai-lab-to-present-phase-1-data-on-novel-dll3-targeted-adc-for-small-cell-lung-cancer-at-asco-2025 2025-04-23T07:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/obi-pharma-s-novel-trop2-adc-obi-902-receives-fda-ind-clearance-for-phase-1-2-trial-using-proprietary-glycobi-r-technology 2025-04-23T07:33:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/obi-pharma-s-novel-trop2-adc-obi-902-receives-fda-ind-clearance-for-phase-1-2-trial-using-proprietary-glycobi-r-technology 2025-04-23T07:33:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-avava-s-focal-point-technology-for-acne-scar-treatment-across-all-skin-types 2025-04-23T07:33:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-avava-s-focal-point-technology-for-acne-scar-treatment-across-all-skin-types 2025-04-23T07:33:50+00:00 hourly 0.9 https://trial.medpath.com/news/novita-s-fascin-inhibitor-np-g2-044-shows-promising-results-in-phase-2-trial-for-advanced-solid-tumors 2025-04-23T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novita-s-fascin-inhibitor-np-g2-044-shows-promising-results-in-phase-2-trial-for-advanced-solid-tumors 2025-04-23T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/mallinckrodt-to-present-five-clinical-studies-on-terlivaz-for-hepatorenal-syndrome-at-ddw-2025 2025-04-23T06:52:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mallinckrodt-to-present-five-clinical-studies-on-terlivaz-for-hepatorenal-syndrome-at-ddw-2025 2025-04-23T06:52:00+00:00 hourly 0.9 https://trial.medpath.com/news/abtherx-partners-with-rondo-and-spice-biotechnologies-to-accelerate-bispecific-antibody-development-for-cancer-immunotherapy 2025-04-23T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abtherx-partners-with-rondo-and-spice-biotechnologies-to-accelerate-bispecific-antibody-development-for-cancer-immunotherapy 2025-04-23T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pacbio-partners-with-davos-alzheimer-s-collaborative-on-groundbreaking-north-african-dementia-registry 2025-04-23T05:18:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pacbio-partners-with-davos-alzheimer-s-collaborative-on-groundbreaking-north-african-dementia-registry 2025-04-23T05:18:27+00:00 hourly 0.9 https://trial.medpath.com/news/genscript-biotech-and-nsg-bio-form-strategic-partnership-to-accelerate-biotech-innovation-in-singapore 2025-04-23T04:34:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genscript-biotech-and-nsg-bio-form-strategic-partnership-to-accelerate-biotech-innovation-in-singapore 2025-04-23T04:34:26+00:00 hourly 0.9 https://trial.medpath.com/news/ctdna-monitoring-shows-promise-for-predicting-melanoma-recurrence-after-surgery 2025-04-23T02:35:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ctdna-monitoring-shows-promise-for-predicting-melanoma-recurrence-after-surgery 2025-04-23T02:35:02+00:00 hourly 0.9 https://trial.medpath.com/news/arbutus-biopharma-to-present-promising-imdusiran-and-ab-101-data-for-chronic-hepatitis-b-at-easl-congress-2025 2025-04-23T02:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arbutus-biopharma-to-present-promising-imdusiran-and-ab-101-data-for-chronic-hepatitis-b-at-easl-congress-2025 2025-04-23T02:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-partners-with-concertai-to-accelerate-precision-oncology-drug-development-using-ai 2025-04-23T02:04:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-partners-with-concertai-to-accelerate-precision-oncology-drug-development-using-ai 2025-04-23T02:04:44+00:00 hourly 0.9 https://trial.medpath.com/news/recursion-s-rec-4881-shows-30-polyp-reduction-in-fap-patients-in-phase-1b-2-trial 2025-04-23T01:35:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recursion-s-rec-4881-shows-30-polyp-reduction-in-fap-patients-in-phase-1b-2-trial 2025-04-23T01:35:23+00:00 hourly 0.9 https://trial.medpath.com/news/sonoma-pharmaceuticals-hypochlorous-acid-based-acne-products-gain-uk-regulatory-approval 2025-04-23T01:35:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sonoma-pharmaceuticals-hypochlorous-acid-based-acne-products-gain-uk-regulatory-approval 2025-04-23T01:35:21+00:00 hourly 0.9 https://trial.medpath.com/news/sobi-showcases-efanesoctocog-alfa-data-from-xtend-phase-3-program-at-wfh-2025-summit 2025-04-23T01:27:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sobi-showcases-efanesoctocog-alfa-data-from-xtend-phase-3-program-at-wfh-2025-summit 2025-04-23T01:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/valneva-pfizer-lyme-disease-vaccine-shows-promise-with-strong-booster-response-in-phase-2-trial 2025-04-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/valneva-pfizer-lyme-disease-vaccine-shows-promise-with-strong-booster-response-in-phase-2-trial 2025-04-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/1cell-ai-launches-oncoincytes-revolutionary-multi-modal-cancer-diagnostic-panel-for-precision-oncology 2025-04-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/1cell-ai-launches-oncoincytes-revolutionary-multi-modal-cancer-diagnostic-panel-for-precision-oncology 2025-04-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/lilly-s-olumiant-shows-promise-in-preserving-beta-cell-function-in-type-1-diabetes 2025-04-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lilly-s-olumiant-shows-promise-in-preserving-beta-cell-function-in-type-1-diabetes 2025-04-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/migraine-treatment-pipeline-shows-robust-activity-with-30-companies-advancing-novel-therapies-through-clinical-trials 2025-04-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/migraine-treatment-pipeline-shows-robust-activity-with-30-companies-advancing-novel-therapies-through-clinical-trials 2025-04-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/wearable-devices-receives-u-s-patent-for-hybrid-voice-and-gesture-control-technology 2025-04-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wearable-devices-receives-u-s-patent-for-hybrid-voice-and-gesture-control-technology 2025-04-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/gene-solutions-and-element-biosciences-form-strategic-alliance-to-expand-ngs-technology-access-across-global-markets 2025-04-22T23:42:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gene-solutions-and-element-biosciences-form-strategic-alliance-to-expand-ngs-technology-access-across-global-markets 2025-04-22T23:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/galapagos-ceo-paul-stoffels-to-step-down-as-company-splits-into-two-entities 2025-04-22T23:09:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galapagos-ceo-paul-stoffels-to-step-down-as-company-splits-into-two-entities 2025-04-22T23:09:56+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-s-cobenfy-fails-to-meet-primary-endpoint-as-adjunctive-schizophrenia-treatment-in-phase-3-arise-trial 2025-04-22T22:35:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bristol-myers-squibb-s-cobenfy-fails-to-meet-primary-endpoint-as-adjunctive-schizophrenia-treatment-in-phase-3-arise-trial 2025-04-22T22:35:13+00:00 hourly 0.9 https://trial.medpath.com/news/novonesis-invests-5-million-to-expand-biotechnology-operations-in-salem-virginia 2025-04-22T22:35:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novonesis-invests-5-million-to-expand-biotechnology-operations-in-salem-virginia 2025-04-22T22:35:09+00:00 hourly 0.9 https://trial.medpath.com/news/springworks-ogsiveo-expected-to-receive-positive-chmp-opinion-boosting-european-market-potential 2025-04-22T19:36:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/springworks-ogsiveo-expected-to-receive-positive-chmp-opinion-boosting-european-market-potential 2025-04-22T19:36:30+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-ark-surgical-s-lapbox-power-first-dual-wall-system-for-both-manual-and-power-morcellation 2025-04-22T19:36:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-ark-surgical-s-lapbox-power-first-dual-wall-system-for-both-manual-and-power-morcellation 2025-04-22T19:36:27+00:00 hourly 0.9 https://trial.medpath.com/news/metro-international-biotech-initiates-phase-1a-trial-of-novel-nad-booster-mib-725-for-age-related-diseases 2025-04-22T19:36:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metro-international-biotech-initiates-phase-1a-trial-of-novel-nad-booster-mib-725-for-age-related-diseases 2025-04-22T19:36:16+00:00 hourly 0.9 https://trial.medpath.com/news/elite-clinical-network-and-healthyu-clinics-form-strategic-partnership-to-transform-clinical-research-access 2025-04-22T19:35:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elite-clinical-network-and-healthyu-clinics-form-strategic-partnership-to-transform-clinical-research-access 2025-04-22T19:35:49+00:00 hourly 0.9 https://trial.medpath.com/news/axoft-s-ultrasoft-brain-computer-interface-shows-promising-results-in-first-human-trial 2025-04-22T17:35:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/axoft-s-ultrasoft-brain-computer-interface-shows-promising-results-in-first-human-trial 2025-04-22T17:35:37+00:00 hourly 0.9 https://trial.medpath.com/news/halda-therapeutics-appoints-dr-eyal-attar-as-chief-medical-officer-to-advance-novel-riptac-cancer-platform 2025-04-22T17:35:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/halda-therapeutics-appoints-dr-eyal-attar-as-chief-medical-officer-to-advance-novel-riptac-cancer-platform 2025-04-22T17:35:36+00:00 hourly 0.9 https://trial.medpath.com/news/smsbiotech-partners-with-u-s-army-to-develop-stem-cell-therapy-for-chemical-warfare-injuries 2025-04-22T16:40:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/smsbiotech-partners-with-u-s-army-to-develop-stem-cell-therapy-for-chemical-warfare-injuries 2025-04-22T16:40:14+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-luminopia-s-digital-therapeutic-approval-for-amblyopia-treatment-to-children-aged-8-12 2025-04-22T16:39:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-expands-luminopia-s-digital-therapeutic-approval-for-amblyopia-treatment-to-children-aged-8-12 2025-04-22T16:39:18+00:00 hourly 0.9 https://trial.medpath.com/news/biostate-ai-and-weill-cornell-medicine-partner-to-develop-ai-driven-personalized-treatment-models-for-leukemia 2025-04-22T16:39:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biostate-ai-and-weill-cornell-medicine-partner-to-develop-ai-driven-personalized-treatment-models-for-leukemia 2025-04-22T16:39:16+00:00 hourly 0.9 https://trial.medpath.com/news/immune-checkpoint-inhibitors-equally-effective-in-older-and-younger-cancer-patients-despite-immune-phenotype-differences 2025-04-22T16:39:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immune-checkpoint-inhibitors-equally-effective-in-older-and-younger-cancer-patients-despite-immune-phenotype-differences 2025-04-22T16:39:14+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-first-in-class-antibody-drug-conjugate-tgw101-for-advanced-solid-tumor-clinical-trial 2025-04-22T16:39:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-first-in-class-antibody-drug-conjugate-tgw101-for-advanced-solid-tumor-clinical-trial 2025-04-22T16:39:10+00:00 hourly 0.9 https://trial.medpath.com/news/sirona-biochem-forms-strategic-partnership-with-promura-gmbh-secures-3m-investment-for-anti-aging-product-development 2025-04-22T16:39:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sirona-biochem-forms-strategic-partnership-with-promura-gmbh-secures-3m-investment-for-anti-aging-product-development 2025-04-22T16:39:02+00:00 hourly 0.9 https://trial.medpath.com/news/eu-biosimilar-filings-opinions-and-approvals 2025-04-22T16:38:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eu-biosimilar-filings-opinions-and-approvals 2025-04-22T16:38:30+00:00 hourly 0.9 https://trial.medpath.com/news/ocumetics-advances-revolutionary-accommodating-intraocular-lens-to-first-in-human-surgery-this-summer 2025-04-22T16:37:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ocumetics-advances-revolutionary-accommodating-intraocular-lens-to-first-in-human-surgery-this-summer 2025-04-22T16:37:44+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-considers-international-reference-pricing-to-slash-u-s-drug-costs 2025-04-22T16:36:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-administration-considers-international-reference-pricing-to-slash-u-s-drug-costs 2025-04-22T16:36:53+00:00 hourly 0.9 https://trial.medpath.com/news/perfuze-completes-enrollment-in-pivotal-stroke-treatment-trial-strengthens-leadership-team 2025-04-22T16:36:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/perfuze-completes-enrollment-in-pivotal-stroke-treatment-trial-strengthens-leadership-team 2025-04-22T16:36:51+00:00 hourly 0.9 https://trial.medpath.com/news/roche-and-regeneron-announce-multi-billion-dollar-investments-in-us-manufacturing-amid-tariff-concerns 2025-04-22T16:35:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-and-regeneron-announce-multi-billion-dollar-investments-in-us-manufacturing-amid-tariff-concerns 2025-04-22T16:35:56+00:00 hourly 0.9 https://trial.medpath.com/news/ibio-licenses-first-in-class-antibody-targeting-activin-e-for-obesity-and-cardiometabolic-diseases 2025-04-22T16:35:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ibio-licenses-first-in-class-antibody-targeting-activin-e-for-obesity-and-cardiometabolic-diseases 2025-04-22T16:35:54+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-brainchild-bio-s-car-t-cell-therapy-for-fatal-pediatric-brain-tumors 2025-04-22T16:35:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-designation-to-brainchild-bio-s-car-t-cell-therapy-for-fatal-pediatric-brain-tumors 2025-04-22T16:35:38+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-device-designation-to-orchestra-biomed-s-avim-therapy-for-hypertension 2025-04-22T16:34:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-device-designation-to-orchestra-biomed-s-avim-therapy-for-hypertension 2025-04-22T16:34:46+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-expands-biologic-manufacturing-capacity-with-3-billion-fujifilm-partnership 2025-04-22T16:34:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-expands-biologic-manufacturing-capacity-with-3-billion-fujifilm-partnership 2025-04-22T16:34:14+00:00 hourly 0.9 https://trial.medpath.com/news/malaysia-strengthens-clinical-research-infrastructure-through-strategic-partnerships-and-record-breaking-trial-activity 2025-04-22T16:34:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/malaysia-strengthens-clinical-research-infrastructure-through-strategic-partnerships-and-record-breaking-trial-activity 2025-04-22T16:34:13+00:00 hourly 0.9 https://trial.medpath.com/news/carthera-enrolls-100-patients-in-landmark-sonobird-trial-using-ultrasound-to-breach-blood-brain-barrier-in-glioblastoma 2025-04-22T16:33:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/carthera-enrolls-100-patients-in-landmark-sonobird-trial-using-ultrasound-to-breach-blood-brain-barrier-in-glioblastoma 2025-04-22T16:33:29+00:00 hourly 0.9 https://trial.medpath.com/news/neurovation-labs-secures-patent-for-novel-ptsd-biomarker-detection-technology 2025-04-22T15:02:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurovation-labs-secures-patent-for-novel-ptsd-biomarker-detection-technology 2025-04-22T15:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/engineered-microglia-a-revolutionary-approach-to-treating-alzheimer-s-disease 2025-04-22T13:28:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/engineered-microglia-a-revolutionary-approach-to-treating-alzheimer-s-disease 2025-04-22T13:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/design-therapeutics-to-present-phase-1-data-for-novel-fecd-eye-drop-treatment-at-ophthalmology-conference 2025-04-22T11:03:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/design-therapeutics-to-present-phase-1-data-for-novel-fecd-eye-drop-treatment-at-ophthalmology-conference 2025-04-22T11:03:29+00:00 hourly 0.9 https://trial.medpath.com/news/cellenkos-novel-off-the-shelf-treg-cell-therapy-demonstrates-promising-results-in-als-clinical-study 2025-04-22T10:43:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellenkos-novel-off-the-shelf-treg-cell-therapy-demonstrates-promising-results-in-als-clinical-study 2025-04-22T10:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/lipum-s-sol-116-shows-promising-phase-i-results-for-rheumatoid-arthritis-treatment 2025-04-22T10:36:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lipum-s-sol-116-shows-promising-phase-i-results-for-rheumatoid-arthritis-treatment 2025-04-22T10:36:13+00:00 hourly 0.9 https://trial.medpath.com/news/invivoscribe-s-labpmm-secures-new-york-state-approval-for-ultra-sensitive-flt3-itd-mrd-assay-in-aml 2025-04-22T10:36:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/invivoscribe-s-labpmm-secures-new-york-state-approval-for-ultra-sensitive-flt3-itd-mrd-assay-in-aml 2025-04-22T10:36:10+00:00 hourly 0.9 https://trial.medpath.com/news/1stbio-and-ligachembio-form-strategic-alliance-to-develop-next-generation-oncology-therapeutics 2025-04-22T10:36:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/1stbio-and-ligachembio-form-strategic-alliance-to-develop-next-generation-oncology-therapeutics 2025-04-22T10:36:08+00:00 hourly 0.9 https://trial.medpath.com/news/enhertu-demonstrates-progression-free-survival-benefits-in-advanced-breast-cancer-trial 2025-04-22T10:36:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enhertu-demonstrates-progression-free-survival-benefits-in-advanced-breast-cancer-trial 2025-04-22T10:36:01+00:00 hourly 0.9 https://trial.medpath.com/news/vivasure-medical-secures-ce-mark-for-first-fully-absorbable-large-bore-vascular-closure-system 2025-04-22T09:36:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vivasure-medical-secures-ce-mark-for-first-fully-absorbable-large-bore-vascular-closure-system 2025-04-22T09:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/guardant-health-s-shield-multi-cancer-detection-test-shows-strong-performance-across-10-cancer-types 2025-04-22T08:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/guardant-health-s-shield-multi-cancer-detection-test-shows-strong-performance-across-10-cancer-types 2025-04-22T08:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-ensem-therapeutics-ind-for-novel-pi3ka-inhibitor-etx-636-for-advanced-cancer-treatment 2025-04-22T08:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-ensem-therapeutics-ind-for-novel-pi3ka-inhibitor-etx-636-for-advanced-cancer-treatment 2025-04-22T08:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/arvinas-to-present-promising-preclinical-data-on-protac-bcl6-degrader-arv-393-at-aacr-2025 2025-04-22T07:33:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arvinas-to-present-promising-preclinical-data-on-protac-bcl6-degrader-arv-393-at-aacr-2025 2025-04-22T07:33:51+00:00 hourly 0.9 https://trial.medpath.com/news/gut-microbiome-metabolite-hya-shows-promise-for-blood-sugar-management-in-type-1-diabetes 2025-04-22T06:19:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gut-microbiome-metabolite-hya-shows-promise-for-blood-sugar-management-in-type-1-diabetes 2025-04-22T06:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/personalis-to-present-new-data-on-next-personal-ctdna-test-for-early-cancer-detection-at-major-oncology-conferences 2025-04-22T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/personalis-to-present-new-data-on-next-personal-ctdna-test-for-early-cancer-detection-at-major-oncology-conferences 2025-04-22T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novocure-s-optune-lua-receives-ce-mark-for-metastatic-non-small-cell-lung-cancer-treatment 2025-04-22T04:09:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novocure-s-optune-lua-receives-ce-mark-for-metastatic-non-small-cell-lung-cancer-treatment 2025-04-22T04:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/ernexa-therapeutics-to-present-promising-erna-101-data-for-ovarian-cancer-at-aacr-2025 2025-04-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ernexa-therapeutics-to-present-promising-erna-101-data-for-ovarian-cancer-at-aacr-2025 2025-04-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/minoryx-and-neuraxpharm-submit-new-marketing-authorization-application-for-leriglitazone-in-cerebral-adrenoleukodystrophy 2025-04-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/minoryx-and-neuraxpharm-submit-new-marketing-authorization-application-for-leriglitazone-in-cerebral-adrenoleukodystrophy 2025-04-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/transneural-therapeutics-unveils-novel-non-hallucinogenic-neuroplastogens-for-neuropsychiatric-disorders 2025-04-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/transneural-therapeutics-unveils-novel-non-hallucinogenic-neuroplastogens-for-neuropsychiatric-disorders 2025-04-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/surveil-dcb-shows-comparable-efficacy-to-in-pact-admiral-with-75-lower-paclitaxel-dose-in-transcend-trial 2025-04-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/surveil-dcb-shows-comparable-efficacy-to-in-pact-admiral-with-75-lower-paclitaxel-dose-in-transcend-trial 2025-04-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-at-ut-health-san-antonio-chemical-endocytic-strategy-could-transform-iv-drugs-into-oral-treatments 2025-04-21T23:03:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-at-ut-health-san-antonio-chemical-endocytic-strategy-could-transform-iv-drugs-into-oral-treatments 2025-04-21T23:03:37+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-neuronos-for-phelan-mcdermid-syndrome-treatment 2025-04-21T22:37:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-neuronos-for-phelan-mcdermid-syndrome-treatment 2025-04-21T22:37:25+00:00 hourly 0.9 https://trial.medpath.com/news/dual-targeted-car-t-cell-therapy-shows-100-response-rate-in-relapsed-refractory-mantle-cell-lymphoma 2025-04-21T19:35:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dual-targeted-car-t-cell-therapy-shows-100-response-rate-in-relapsed-refractory-mantle-cell-lymphoma 2025-04-21T19:35:46+00:00 hourly 0.9 https://trial.medpath.com/news/experimental-cancer-drug-navitoclax-shows-promise-in-enhancing-tuberculosis-treatment 2025-04-21T19:34:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/experimental-cancer-drug-navitoclax-shows-promise-in-enhancing-tuberculosis-treatment 2025-04-21T19:34:52+00:00 hourly 0.9 https://trial.medpath.com/news/vcu-massey-becomes-first-virginia-center-to-offer-robotic-hifu-for-prostate-cancer-treatment 2025-04-21T17:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vcu-massey-becomes-first-virginia-center-to-offer-robotic-hifu-for-prostate-cancer-treatment 2025-04-21T17:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/field-medical-secures-40-million-series-a-financing-to-advance-pulsed-field-ablation-for-ventricular-tachycardia 2025-04-21T16:41:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/field-medical-secures-40-million-series-a-financing-to-advance-pulsed-field-ablation-for-ventricular-tachycardia 2025-04-21T16:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/long-term-study-confirms-hydroxyurea-s-safety-and-efficacy-in-pediatric-sickle-cell-disease 2025-04-21T16:40:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-term-study-confirms-hydroxyurea-s-safety-and-efficacy-in-pediatric-sickle-cell-disease 2025-04-21T16:40:50+00:00 hourly 0.9 https://trial.medpath.com/news/titan-x-ai-platform-accelerates-development-of-novel-immunoregulatory-therapeutics-for-autoimmune-diseases 2025-04-21T16:40:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/titan-x-ai-platform-accelerates-development-of-novel-immunoregulatory-therapeutics-for-autoimmune-diseases 2025-04-21T16:40:19+00:00 hourly 0.9 https://trial.medpath.com/news/nadofaragene-firadenovec-shows-75-complete-response-rate-in-japanese-phase-3-trial-for-bcg-unresponsive-bladder-cancer 2025-04-21T16:40:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nadofaragene-firadenovec-shows-75-complete-response-rate-in-japanese-phase-3-trial-for-bcg-unresponsive-bladder-cancer 2025-04-21T16:40:14+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-24-of-difficult-to-control-type-2-diabetes-patients-have-hypercortisolism 2025-04-21T16:40:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-24-of-difficult-to-control-type-2-diabetes-patients-have-hypercortisolism 2025-04-21T16:40:12+00:00 hourly 0.9 https://trial.medpath.com/news/fda-commissioner-makary-proposes-new-approval-pathway-for-rare-disease-drugs 2025-04-21T16:39:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-commissioner-makary-proposes-new-approval-pathway-for-rare-disease-drugs 2025-04-21T16:39:15+00:00 hourly 0.9 https://trial.medpath.com/news/sunshine-biopharma-launches-generic-everolimus-in-canada-s-2-5b-oncology-market 2025-04-21T16:39:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sunshine-biopharma-launches-generic-everolimus-in-canada-s-2-5b-oncology-market 2025-04-21T16:39:14+00:00 hourly 0.9 https://trial.medpath.com/news/mural-oncology-cuts-90-of-workforce-following-failed-cancer-immunotherapy-trials 2025-04-21T16:38:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mural-oncology-cuts-90-of-workforce-following-failed-cancer-immunotherapy-trials 2025-04-21T16:38:55+00:00 hourly 0.9 https://trial.medpath.com/news/vaccinex-s-pepinemab-shows-promise-in-turning-cold-tumors-hot-through-enhanced-immune-response 2025-04-21T16:38:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vaccinex-s-pepinemab-shows-promise-in-turning-cold-tumors-hot-through-enhanced-immune-response 2025-04-21T16:38:53+00:00 hourly 0.9 https://trial.medpath.com/news/stanford-researchers-develop-novel-rna-blood-test-for-cancer-detection-and-treatment-resistance-monitoring 2025-04-21T16:38:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stanford-researchers-develop-novel-rna-blood-test-for-cancer-detection-and-treatment-resistance-monitoring 2025-04-21T16:38:48+00:00 hourly 0.9 https://trial.medpath.com/news/genesight-test-reduces-psychiatric-hospitalizations-in-major-depression-patients-study-shows 2025-04-21T16:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genesight-test-reduces-psychiatric-hospitalizations-in-major-depression-patients-study-shows 2025-04-21T16:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/icl-to-acquire-lavie-bio-strategic-move-to-advance-ai-driven-agricultural-biologicals 2025-04-21T14:03:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/icl-to-acquire-lavie-bio-strategic-move-to-advance-ai-driven-agricultural-biologicals 2025-04-21T14:03:21+00:00 hourly 0.9 https://trial.medpath.com/news/grand-pharmaceutical-s-stc3141-shows-promise-in-phase-ii-sepsis-treatment-trial 2025-04-21T13:34:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/grand-pharmaceutical-s-stc3141-shows-promise-in-phase-ii-sepsis-treatment-trial 2025-04-21T13:34:47+00:00 hourly 0.9 https://trial.medpath.com/news/invivyd-secures-30m-non-dilutive-loan-facility-to-advance-covid-19-antibody-pipeline 2025-04-21T13:34:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/invivyd-secures-30m-non-dilutive-loan-facility-to-advance-covid-19-antibody-pipeline 2025-04-21T13:34:09+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-ns-229-for-rare-vasculitis-condition 2025-04-21T13:34:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-ns-229-for-rare-vasculitis-condition 2025-04-21T13:34:08+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-enters-indian-oncology-market-with-venetoclax-for-blood-cancer-treatment 2025-04-21T13:34:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-enters-indian-oncology-market-with-venetoclax-for-blood-cancer-treatment 2025-04-21T13:34:05+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-groundbreaking-gene-therapy-for-dystrophic-epidermolysis-bullosa 2025-04-21T13:33:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-groundbreaking-gene-therapy-for-dystrophic-epidermolysis-bullosa 2025-04-21T13:33:56+00:00 hourly 0.9 https://trial.medpath.com/news/nanog-inhibition-shows-promising-results-in-glioblastoma-treatment-significantly-enhancing-temozolomide-efficacy 2025-04-21T11:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanog-inhibition-shows-promising-results-in-glioblastoma-treatment-significantly-enhancing-temozolomide-efficacy 2025-04-21T11:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-dupilumab-for-chronic-spontaneous-urticaria-expanding-treatment-options 2025-04-21T11:03:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-dupilumab-for-chronic-spontaneous-urticaria-expanding-treatment-options 2025-04-21T11:03:13+00:00 hourly 0.9 https://trial.medpath.com/news/vgenomics-and-meril-genomics-form-strategic-alliance-to-transform-precision-medicine-landscape-in-india 2025-04-21T10:36:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vgenomics-and-meril-genomics-form-strategic-alliance-to-transform-precision-medicine-landscape-in-india 2025-04-21T10:36:36+00:00 hourly 0.9 https://trial.medpath.com/news/cgbio-s-novosis-putty-receives-fda-approval-for-pivotal-us-clinical-trials 2025-04-21T10:36:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cgbio-s-novosis-putty-receives-fda-approval-for-pivotal-us-clinical-trials 2025-04-21T10:36:24+00:00 hourly 0.9 https://trial.medpath.com/news/toolgen-files-patent-infringement-lawsuit-against-vertex-over-crispr-gene-therapy-casgevy 2025-04-21T10:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/toolgen-files-patent-infringement-lawsuit-against-vertex-over-crispr-gene-therapy-casgevy 2025-04-21T10:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/inocras-and-d3b-launch-collaborative-research-to-decode-rare-sinonasal-cancer-genetics 2025-04-21T07:38:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inocras-and-d3b-launch-collaborative-research-to-decode-rare-sinonasal-cancer-genetics 2025-04-21T07:38:00+00:00 hourly 0.9 https://trial.medpath.com/news/spring-allergy-management-expert-guidelines-for-comprehensive-patient-care 2025-04-21T04:03:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spring-allergy-management-expert-guidelines-for-comprehensive-patient-care 2025-04-21T04:03:58+00:00 hourly 0.9 https://trial.medpath.com/news/apollo-hospital-and-kims-sunshine-partner-with-medtronic-to-launch-renal-denervation-therapy-centers-for-resistant-hypertension 2025-04-21T01:33:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apollo-hospital-and-kims-sunshine-partner-with-medtronic-to-launch-renal-denervation-therapy-centers-for-resistant-hypertension 2025-04-21T01:33:23+00:00 hourly 0.9 https://trial.medpath.com/news/taipei-medical-university-and-msd-taiwan-forge-landmark-healthcare-innovation-partnership 2025-04-21T01:33:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/taipei-medical-university-and-msd-taiwan-forge-landmark-healthcare-innovation-partnership 2025-04-21T01:33:16+00:00 hourly 0.9 https://trial.medpath.com/news/cemiplimab-shows-significant-survival-benefit-in-nsclc-patients-with-brain-metastases-and-high-pd-l1-expression 2025-04-20T22:38:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cemiplimab-shows-significant-survival-benefit-in-nsclc-patients-with-brain-metastases-and-high-pd-l1-expression 2025-04-20T22:38:05+00:00 hourly 0.9 https://trial.medpath.com/news/cipla-advances-inhaled-antifungal-therapy-with-phase-iii-trial-approval-for-itraconazole-dry-powder 2025-04-20T19:36:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cipla-advances-inhaled-antifungal-therapy-with-phase-iii-trial-approval-for-itraconazole-dry-powder 2025-04-20T19:36:06+00:00 hourly 0.9 https://trial.medpath.com/news/senate-judiciary-committee-advances-six-bipartisan-bills-to-combat-high-drug-prices 2025-04-20T16:34:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senate-judiciary-committee-advances-six-bipartisan-bills-to-combat-high-drug-prices 2025-04-20T16:34:19+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-trial-shows-high-dose-radiotherapy-significantly-improves-survival-in-limited-stage-small-cell-lung-cancer 2025-04-20T16:33:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3-trial-shows-high-dose-radiotherapy-significantly-improves-survival-in-limited-stage-small-cell-lung-cancer 2025-04-20T16:33:41+00:00 hourly 0.9 https://trial.medpath.com/news/unauthorized-drug-trials-exposed-at-ahmedabad-s-vs-hospital-over-500-patients-affected 2025-04-20T04:33:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/unauthorized-drug-trials-exposed-at-ahmedabad-s-vs-hospital-over-500-patients-affected 2025-04-20T04:33:14+00:00 hourly 0.9 https://trial.medpath.com/news/f2g-s-novel-antifungal-olorofim-shows-promise-despite-fda-setback-phase-2b-results-published-in-the-lancet 2025-04-19T20:02:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/f2g-s-novel-antifungal-olorofim-shows-promise-despite-fda-setback-phase-2b-results-published-in-the-lancet 2025-04-19T20:02:28+00:00 hourly 0.9 https://trial.medpath.com/news/novel-mini-protein-aky-1189-shows-promise-in-targeted-radiation-delivery-for-multiple-cancer-types 2025-04-19T19:33:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-mini-protein-aky-1189-shows-promise-in-targeted-radiation-delivery-for-multiple-cancer-types 2025-04-19T19:33:32+00:00 hourly 0.9 https://trial.medpath.com/news/u-s-measles-outbreak-reaches-800-cases-marking-largest-since-disease-elimination-in-2000 2025-04-19T19:33:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/u-s-measles-outbreak-reaches-800-cases-marking-largest-since-disease-elimination-in-2000 2025-04-19T19:33:12+00:00 hourly 0.9 https://trial.medpath.com/news/uncomplicated-utis-impose-significant-economic-burden-on-healthcare-systems 2025-04-19T17:03:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uncomplicated-utis-impose-significant-economic-burden-on-healthcare-systems 2025-04-19T17:03:58+00:00 hourly 0.9 https://trial.medpath.com/news/chime-biologics-and-polpharma-biologics-form-strategic-partnership-to-accelerate-global-biosimilar-development 2025-04-19T16:33:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chime-biologics-and-polpharma-biologics-form-strategic-partnership-to-accelerate-global-biosimilar-development 2025-04-19T16:33:41+00:00 hourly 0.9 https://trial.medpath.com/news/biologic-drug-costs-for-psoriasis-more-than-doubled-between-2007-2021-study-reveals 2025-04-19T16:33:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biologic-drug-costs-for-psoriasis-more-than-doubled-between-2007-2021-study-reveals 2025-04-19T16:33:25+00:00 hourly 0.9 https://trial.medpath.com/news/fda-restricts-industry-representatives-on-advisory-committees-to-restore-public-trust 2025-04-19T16:33:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-restricts-industry-representatives-on-advisory-committees-to-restore-public-trust 2025-04-19T16:33:23+00:00 hourly 0.9 https://trial.medpath.com/news/fda-updates-camzyos-label-reduced-monitoring-requirements-and-expanded-patient-eligibility-for-hcm-treatment 2025-04-19T01:39:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-updates-camzyos-label-reduced-monitoring-requirements-and-expanded-patient-eligibility-for-hcm-treatment 2025-04-19T01:39:05+00:00 hourly 0.9 https://trial.medpath.com/news/former-operation-warp-speed-leader-dr-matthew-hepburn-joins-panther-life-sciences-to-advance-microarray-patch-technology 2025-04-19T01:39:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/former-operation-warp-speed-leader-dr-matthew-hepburn-joins-panther-life-sciences-to-advance-microarray-patch-technology 2025-04-19T01:39:03+00:00 hourly 0.9 https://trial.medpath.com/news/nusano-secures-major-supply-agreements-with-ratio-therapeutics-and-clarity-pharmaceuticals-to-address-critical-radioisotope-shortage 2025-04-19T01:38:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nusano-secures-major-supply-agreements-with-ratio-therapeutics-and-clarity-pharmaceuticals-to-address-critical-radioisotope-shortage 2025-04-19T01:38:33+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-medtronic-s-simplera-sync-sensor-for-minimed-780g-system-expanding-cgm-options-for-diabetes-management 2025-04-19T01:38:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-medtronic-s-simplera-sync-sensor-for-minimed-780g-system-expanding-cgm-options-for-diabetes-management 2025-04-19T01:38:30+00:00 hourly 0.9 https://trial.medpath.com/news/compass-pathways-psilocybin-therapy-meets-primary-endpoint-in-largest-depression-trial 2025-04-19T01:38:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/compass-pathways-psilocybin-therapy-meets-primary-endpoint-in-largest-depression-trial 2025-04-19T01:38:29+00:00 hourly 0.9 https://trial.medpath.com/news/bms-s-opdualag-shows-strong-early-performance-as-first-lag-3-checkpoint-inhibitor-for-melanoma 2025-04-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bms-s-opdualag-shows-strong-early-performance-as-first-lag-3-checkpoint-inhibitor-for-melanoma 2025-04-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/kyowa-hakko-kirin-partners-with-inveniai-to-accelerate-drug-repurposing-using-ai-technology 2025-04-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kyowa-hakko-kirin-partners-with-inveniai-to-accelerate-drug-repurposing-using-ai-technology 2025-04-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/nference-and-beigene-partner-on-ai-driven-research-to-advance-b-cell-cancer-treatment 2025-04-18T23:34:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nference-and-beigene-partner-on-ai-driven-research-to-advance-b-cell-cancer-treatment 2025-04-18T23:34:27+00:00 hourly 0.9 https://trial.medpath.com/news/sparx-to-present-phase-1-data-on-novel-dual-checkpoint-inhibitor-spx-303-at-aacr-2025 2025-04-18T20:17:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sparx-to-present-phase-1-data-on-novel-dual-checkpoint-inhibitor-spx-303-at-aacr-2025 2025-04-18T20:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/wuxi-biologics-achieves-milestone-with-first-commercial-ppq-campaign-at-15000l-single-use-bioreactor-facility 2025-04-18T20:04:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wuxi-biologics-achieves-milestone-with-first-commercial-ppq-campaign-at-15000l-single-use-bioreactor-facility 2025-04-18T20:04:52+00:00 hourly 0.9 https://trial.medpath.com/news/31-gene-expression-profile-test-safely-identifies-melanoma-patients-who-can-avoid-sentinel-lymph-node-biopsy 2025-04-18T19:34:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/31-gene-expression-profile-test-safely-identifies-melanoma-patients-who-can-avoid-sentinel-lymph-node-biopsy 2025-04-18T19:34:02+00:00 hourly 0.9 https://trial.medpath.com/news/notch1-mutations-predict-superior-immunotherapy-response-in-advanced-esophageal-cancer 2025-04-18T18:52:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/notch1-mutations-predict-superior-immunotherapy-response-in-advanced-esophageal-cancer 2025-04-18T18:52:45+00:00 hourly 0.9 https://trial.medpath.com/news/zydus-medtech-partners-with-braile-biomedica-to-expand-tavi-technology-across-europe-and-india 2025-04-18T18:48:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zydus-medtech-partners-with-braile-biomedica-to-expand-tavi-technology-across-europe-and-india 2025-04-18T18:48:07+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-genus-pic-s-gene-edited-prrs-resistant-pigs-in-landmark-decision 2025-04-18T18:48:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-genus-pic-s-gene-edited-prrs-resistant-pigs-in-landmark-decision 2025-04-18T18:48:06+00:00 hourly 0.9 https://trial.medpath.com/news/long-term-disease-control-observed-in-nsclc-patients-after-immune-checkpoint-inhibitor-discontinuation 2025-04-18T18:47:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-term-disease-control-observed-in-nsclc-patients-after-immune-checkpoint-inhibitor-discontinuation 2025-04-18T18:47:56+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-device-designation-to-alibaba-s-ai-for-early-pancreatic-cancer-detection 2025-04-18T18:46:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-device-designation-to-alibaba-s-ai-for-early-pancreatic-cancer-detection 2025-04-18T18:46:32+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-shows-pepaxti-effective-in-heavily-pretreated-multiple-myeloma-patients 2025-04-18T18:45:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-study-shows-pepaxti-effective-in-heavily-pretreated-multiple-myeloma-patients 2025-04-18T18:45:29+00:00 hourly 0.9 https://trial.medpath.com/news/early-discontinuation-of-adjuvant-immunotherapy-shows-no-negative-impact-on-melanoma-recurrence 2025-04-18T18:45:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/early-discontinuation-of-adjuvant-immunotherapy-shows-no-negative-impact-on-melanoma-recurrence 2025-04-18T18:45:26+00:00 hourly 0.9 https://trial.medpath.com/news/nebraska-becomes-first-state-to-ban-soda-and-energy-drinks-from-snap-program 2025-04-18T18:43:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nebraska-becomes-first-state-to-ban-soda-and-energy-drinks-from-snap-program 2025-04-18T18:43:45+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-cancels-800-million-in-lgbtq-health-research-funding 2025-04-18T18:34:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-administration-cancels-800-million-in-lgbtq-health-research-funding 2025-04-18T18:34:23+00:00 hourly 0.9 https://trial.medpath.com/news/women-with-autoimmune-diseases-face-50-higher-risk-of-heart-related-death-than-men 2025-04-18T18:34:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/women-with-autoimmune-diseases-face-50-higher-risk-of-heart-related-death-than-men 2025-04-18T18:34:09+00:00 hourly 0.9 https://trial.medpath.com/news/fda-recalls-six-acne-products-after-testing-reveals-benzene-contamination-above-safety-limits 2025-04-18T18:30:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-recalls-six-acne-products-after-testing-reveals-benzene-contamination-above-safety-limits 2025-04-18T18:30:36+00:00 hourly 0.9 https://trial.medpath.com/news/u-s-measles-outbreak-intensifies-600-cases-reported-as-hhs-secretary-s-stance-on-vaccines-draws-criticism 2025-04-18T18:30:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/u-s-measles-outbreak-intensifies-600-cases-reported-as-hhs-secretary-s-stance-on-vaccines-draws-criticism 2025-04-18T18:30:34+00:00 hourly 0.9 https://trial.medpath.com/news/ob-gyn-workforce-shifts-following-abortion-bans-new-study-reveals-complex-migration-patterns 2025-04-18T18:30:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ob-gyn-workforce-shifts-following-abortion-bans-new-study-reveals-complex-migration-patterns 2025-04-18T18:30:28+00:00 hourly 0.9 https://trial.medpath.com/news/cdc-reinstates-460-laid-off-employees-amid-ongoing-organizational-turmoil 2025-04-18T18:30:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdc-reinstates-460-laid-off-employees-amid-ongoing-organizational-turmoil 2025-04-18T18:30:23+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-slashes-10000-hhs-jobs-amid-major-restructuring 2025-04-18T18:29:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-administration-slashes-10000-hhs-jobs-amid-major-restructuring 2025-04-18T18:29:17+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-screening-rates-rebound-post-pandemic-but-cervical-cancer-prevention-lags-behind 2025-04-18T18:26:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cancer-screening-rates-rebound-post-pandemic-but-cervical-cancer-prevention-lags-behind 2025-04-18T18:26:52+00:00 hourly 0.9 https://trial.medpath.com/news/ipsen-secures-dual-chmp-approvals-for-rare-liver-disease-treatments-following-regulatory-strategy-shift 2025-04-18T18:26:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ipsen-secures-dual-chmp-approvals-for-rare-liver-disease-treatments-following-regulatory-strategy-shift 2025-04-18T18:26:45+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-reverses-decision-to-end-free-covid-19-test-program 2025-04-18T18:21:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-administration-reverses-decision-to-end-free-covid-19-test-program 2025-04-18T18:21:39+00:00 hourly 0.9 https://trial.medpath.com/news/evidence-review-finds-limited-effective-treatments-for-low-back-pain 2025-04-18T18:21:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evidence-review-finds-limited-effective-treatments-for-low-back-pain 2025-04-18T18:21:03+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-drugs-linked-to-elevated-risk-of-serious-eye-conditions-in-multiple-studies 2025-04-18T18:19:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-drugs-linked-to-elevated-risk-of-serious-eye-conditions-in-multiple-studies 2025-04-18T18:19:03+00:00 hourly 0.9 https://trial.medpath.com/news/heart-disease-mortality-patterns-shift-as-acute-deaths-decline-while-chronic-conditions-rise 2025-04-18T18:16:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/heart-disease-mortality-patterns-shift-as-acute-deaths-decline-while-chronic-conditions-rise 2025-04-18T18:16:22+00:00 hourly 0.9 https://trial.medpath.com/news/heavy-cannabis-use-linked-to-triple-mortality-risk-and-rising-psychosis-cases-studies-find 2025-04-18T18:15:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/heavy-cannabis-use-linked-to-triple-mortality-risk-and-rising-psychosis-cases-studies-find 2025-04-18T18:15:56+00:00 hourly 0.9 https://trial.medpath.com/news/declining-childhood-vaccination-rates-raise-alarm-for-resurgence-of-preventable-diseases 2025-04-18T18:15:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/declining-childhood-vaccination-rates-raise-alarm-for-resurgence-of-preventable-diseases 2025-04-18T18:15:54+00:00 hourly 0.9 https://trial.medpath.com/news/medicare-expands-drug-price-negotiations-to-include-15-high-cost-medications-including-ozempic-and-wegovy 2025-04-18T18:14:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicare-expands-drug-price-negotiations-to-include-15-high-cost-medications-including-ozempic-and-wegovy 2025-04-18T18:14:46+00:00 hourly 0.9 https://trial.medpath.com/news/blood-test-predicts-rapid-alzheimer-s-decline-using-insulin-resistance-marker 2025-04-18T18:08:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blood-test-predicts-rapid-alzheimer-s-decline-using-insulin-resistance-marker 2025-04-18T18:08:03+00:00 hourly 0.9 https://trial.medpath.com/news/risk-reducing-surgeries-significantly-improve-survival-in-brca-positive-breast-cancer-patients 2025-04-18T18:05:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/risk-reducing-surgeries-significantly-improve-survival-in-brca-positive-breast-cancer-patients 2025-04-18T18:05:45+00:00 hourly 0.9 https://trial.medpath.com/news/blood-test-innovations-cbc-analysis-could-revolutionize-disease-detection-and-monitoring 2025-04-18T18:05:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blood-test-innovations-cbc-analysis-could-revolutionize-disease-detection-and-monitoring 2025-04-18T18:05:04+00:00 hourly 0.9 https://trial.medpath.com/news/alcohol-and-substance-use-linked-to-rising-e-scooter-injuries-studies-show 2025-04-18T18:03:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alcohol-and-substance-use-linked-to-rising-e-scooter-injuries-studies-show 2025-04-18T18:03:25+00:00 hourly 0.9 https://trial.medpath.com/news/loneliness-epidemic-shifts-middle-aged-americans-more-isolated-than-seniors-new-research-reveals 2025-04-18T18:03:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/loneliness-epidemic-shifts-middle-aged-americans-more-isolated-than-seniors-new-research-reveals 2025-04-18T18:03:23+00:00 hourly 0.9 https://trial.medpath.com/news/high-fiber-plant-based-diet-shows-promise-in-preventing-multiple-myeloma-progression-in-at-risk-patients 2025-04-18T18:03:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/high-fiber-plant-based-diet-shows-promise-in-preventing-multiple-myeloma-progression-in-at-risk-patients 2025-04-18T18:03:21+00:00 hourly 0.9 https://trial.medpath.com/news/expert-guidance-for-managing-holiday-activities-with-dementia-patients-practical-approaches-for-caregivers 2025-04-18T18:01:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/expert-guidance-for-managing-holiday-activities-with-dementia-patients-practical-approaches-for-caregivers 2025-04-18T18:01:08+00:00 hourly 0.9 https://trial.medpath.com/news/radnet-to-acquire-icad-for-100-million-advancing-ai-powered-breast-cancer-detection 2025-04-18T18:00:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/radnet-to-acquire-icad-for-100-million-advancing-ai-powered-breast-cancer-detection 2025-04-18T18:00:51+00:00 hourly 0.9 https://trial.medpath.com/news/california-child-tests-positive-for-h5n1-bird-flu-without-known-animal-exposure 2025-04-18T17:59:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/california-child-tests-positive-for-h5n1-bird-flu-without-known-animal-exposure 2025-04-18T17:59:54+00:00 hourly 0.9 https://trial.medpath.com/news/medical-imaging-s-climate-impact-unnecessary-scans-contribute-significantly-to-carbon-emissions 2025-04-18T17:59:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medical-imaging-s-climate-impact-unnecessary-scans-contribute-significantly-to-carbon-emissions 2025-04-18T17:59:47+00:00 hourly 0.9 https://trial.medpath.com/news/rising-pancreatic-cancer-rates-in-young-adults-likely-due-to-improved-detection-not-increased-disease-burden 2025-04-18T17:59:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rising-pancreatic-cancer-rates-in-young-adults-likely-due-to-improved-detection-not-increased-disease-burden 2025-04-18T17:59:43+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-diagnostic-tools-for-early-fatty-liver-disease-detection-ai-and-blood-tests-show-promise 2025-04-18T17:59:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-diagnostic-tools-for-early-fatty-liver-disease-detection-ai-and-blood-tests-show-promise 2025-04-18T17:59:39+00:00 hourly 0.9 https://trial.medpath.com/news/er-visits-for-psychedelics-linked-to-higher-mortality-and-schizophrenia-risk-studies-find 2025-04-18T17:58:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/er-visits-for-psychedelics-linked-to-higher-mortality-and-schizophrenia-risk-studies-find 2025-04-18T17:58:15+00:00 hourly 0.9 https://trial.medpath.com/news/ultra-rapid-genetic-test-revolutionizes-brain-cancer-surgery-with-real-time-tumor-detection 2025-04-18T17:58:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ultra-rapid-genetic-test-revolutionizes-brain-cancer-surgery-with-real-time-tumor-detection 2025-04-18T17:58:14+00:00 hourly 0.9 https://trial.medpath.com/news/studies-reveal-concerning-trends-in-prostate-cancer-treatment-overtreatment-rising-despite-serious-long-term-risks 2025-04-18T17:57:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/studies-reveal-concerning-trends-in-prostate-cancer-treatment-overtreatment-rising-despite-serious-long-term-risks 2025-04-18T17:57:28+00:00 hourly 0.9 https://trial.medpath.com/news/first-u-s-case-of-more-virulent-mpox-strain-detected-in-california-traveler 2025-04-18T17:56:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-u-s-case-of-more-virulent-mpox-strain-detected-in-california-traveler 2025-04-18T17:56:53+00:00 hourly 0.9 https://trial.medpath.com/news/mental-health-crisis-deepens-anxiety-and-depression-rates-surge-among-americans-particularly-youth 2025-04-18T17:56:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mental-health-crisis-deepens-anxiety-and-depression-rates-surge-among-americans-particularly-youth 2025-04-18T17:56:50+00:00 hourly 0.9 https://trial.medpath.com/news/mindfulness-and-cbt-significantly-reduce-chronic-low-back-pain-and-opioid-use-in-landmark-clinical-trial 2025-04-18T17:55:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mindfulness-and-cbt-significantly-reduce-chronic-low-back-pain-and-opioid-use-in-landmark-clinical-trial 2025-04-18T17:55:38+00:00 hourly 0.9 https://trial.medpath.com/news/responsive-parenting-and-digital-support-significantly-reduce-childhood-obesity-risk-studies-show 2025-04-18T17:55:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/responsive-parenting-and-digital-support-significantly-reduce-childhood-obesity-risk-studies-show 2025-04-18T17:55:09+00:00 hourly 0.9 https://trial.medpath.com/news/autism-diagnoses-surge-175-in-the-u-s-over-past-decade-study-reveals 2025-04-18T17:54:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/autism-diagnoses-surge-175-in-the-u-s-over-past-decade-study-reveals 2025-04-18T17:54:22+00:00 hourly 0.9 https://trial.medpath.com/news/hormonal-influences-on-asthma-risk-new-studies-reveal-gender-specific-patterns 2025-04-18T17:54:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hormonal-influences-on-asthma-risk-new-studies-reveal-gender-specific-patterns 2025-04-18T17:54:18+00:00 hourly 0.9 https://trial.medpath.com/news/weekend-warrior-exercise-pattern-offers-comparable-brain-health-benefits-to-regular-activity 2025-04-18T17:54:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/weekend-warrior-exercise-pattern-offers-comparable-brain-health-benefits-to-regular-activity 2025-04-18T17:54:17+00:00 hourly 0.9 https://trial.medpath.com/news/gut-microbiome-changes-linked-to-cognitive-decline-and-dementia-in-parkinson-s-disease 2025-04-18T17:53:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gut-microbiome-changes-linked-to-cognitive-decline-and-dementia-in-parkinson-s-disease 2025-04-18T17:53:21+00:00 hourly 0.9 https://trial.medpath.com/news/blue-cross-blue-shield-of-massachusetts-to-end-coverage-for-weight-loss-glp-1-drugs-in-2026 2025-04-18T12:54:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blue-cross-blue-shield-of-massachusetts-to-end-coverage-for-weight-loss-glp-1-drugs-in-2026 2025-04-18T12:54:00+00:00 hourly 0.9 https://trial.medpath.com/news/australia-approves-ifinwil-eflornithine-for-high-risk-neuroblastoma-treatment 2025-04-18T11:03:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australia-approves-ifinwil-eflornithine-for-high-risk-neuroblastoma-treatment 2025-04-18T11:03:21+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-qidp-status-to-venus-remedies-novel-antibiotic-vrp-034-for-bloodstream-infections 2025-04-18T08:03:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-qidp-status-to-venus-remedies-novel-antibiotic-vrp-034-for-bloodstream-infections 2025-04-18T08:03:26+00:00 hourly 0.9 https://trial.medpath.com/news/velavigo-secures-440m-licensing-deal-for-first-in-class-bispecific-antibody-vbs-102 2025-04-18T07:40:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/velavigo-secures-440m-licensing-deal-for-first-in-class-bispecific-antibody-vbs-102 2025-04-18T07:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/chugai-s-vabysmo-becomes-first-approved-treatment-for-angioid-streaks-in-japan 2025-04-18T07:33:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chugai-s-vabysmo-becomes-first-approved-treatment-for-angioid-streaks-in-japan 2025-04-18T07:33:26+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-ind-for-nurix-and-gilead-s-novel-irak4-degrader-gs-6791-nx-0479-for-inflammatory-conditions 2025-04-18T05:33:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-ind-for-nurix-and-gilead-s-novel-irak4-degrader-gs-6791-nx-0479-for-inflammatory-conditions 2025-04-18T05:33:34+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-glasgow-and-mydna-partner-to-advance-pharmacogenomics-integration-in-nhs-healthcare 2025-04-18T05:07:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-glasgow-and-mydna-partner-to-advance-pharmacogenomics-integration-in-nhs-healthcare 2025-04-18T05:07:35+00:00 hourly 0.9 https://trial.medpath.com/news/precision-neuroscience-secures-fda-clearance-for-layer-7-cortical-interface-advancing-bci-technology 2025-04-18T05:07:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precision-neuroscience-secures-fda-clearance-for-layer-7-cortical-interface-advancing-bci-technology 2025-04-18T05:07:34+00:00 hourly 0.9 https://trial.medpath.com/news/hikma-acquires-fda-approved-generic-trametinib-anda-securing-180-day-market-exclusivity 2025-04-18T05:07:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hikma-acquires-fda-approved-generic-trametinib-anda-securing-180-day-market-exclusivity 2025-04-18T05:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/baypine-acquires-cenexel-clinical-research-aims-to-transform-clinical-trial-operations 2025-04-18T05:07:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/baypine-acquires-cenexel-clinical-research-aims-to-transform-clinical-trial-operations 2025-04-18T05:07:20+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-s-oral-glp-1-orforglipron-shows-promising-phase-3-results-for-weight-management 2025-04-18T03:05:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-s-oral-glp-1-orforglipron-shows-promising-phase-3-results-for-weight-management 2025-04-18T03:05:52+00:00 hourly 0.9 https://trial.medpath.com/news/promising-therapeutic-advances-for-rare-lymphomas-pi3k-inhibitors-ezh2-inhibitors-and-immunotherapy-show-clinical-potential 2025-04-18T03:05:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/promising-therapeutic-advances-for-rare-lymphomas-pi3k-inhibitors-ezh2-inhibitors-and-immunotherapy-show-clinical-potential 2025-04-18T03:05:31+00:00 hourly 0.9 https://trial.medpath.com/news/endevica-bio-initiates-phase-2-trial-of-tcmcb07-for-cancer-cachexia-in-metastatic-colorectal-cancer-patients 2025-04-18T02:04:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/endevica-bio-initiates-phase-2-trial-of-tcmcb07-for-cancer-cachexia-in-metastatic-colorectal-cancer-patients 2025-04-18T02:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/elraglusib-shows-promise-for-advanced-salivary-gland-carcinoma-in-upcoming-aacr-presentation 2025-04-18T02:03:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elraglusib-shows-promise-for-advanced-salivary-gland-carcinoma-in-upcoming-aacr-presentation 2025-04-18T02:03:27+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-initiates-phase-2-trial-of-sar441566-for-moderate-to-severe-ulcerative-colitis 2025-04-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-initiates-phase-2-trial-of-sar441566-for-moderate-to-severe-ulcerative-colitis 2025-04-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-and-qure-ai-reach-5-million-ai-powered-chest-x-rays-for-lung-cancer-detection-across-20-countries 2025-04-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-and-qure-ai-reach-5-million-ai-powered-chest-x-rays-for-lung-cancer-detection-across-20-countries 2025-04-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/balancing-efficacy-and-cost-sustainability-in-modern-cll-treatment-insights-from-dr-pierluigi-porcu 2025-04-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/balancing-efficacy-and-cost-sustainability-in-modern-cll-treatment-insights-from-dr-pierluigi-porcu 2025-04-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/genedx-acquires-fabric-genomics-for-up-to-51-million-to-expand-global-genomic-diagnostics 2025-04-17T23:33:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genedx-acquires-fabric-genomics-for-up-to-51-million-to-expand-global-genomic-diagnostics 2025-04-17T23:33:56+00:00 hourly 0.9 https://trial.medpath.com/news/ai-in-healthcare-standardization-and-collaboration-key-to-future-success-experts-say 2025-04-17T22:03:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-in-healthcare-standardization-and-collaboration-key-to-future-success-experts-say 2025-04-17T22:03:52+00:00 hourly 0.9 https://trial.medpath.com/news/who-member-states-reach-historic-draft-pandemic-agreement-after-three-years-of-negotiations 2025-04-17T22:03:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/who-member-states-reach-historic-draft-pandemic-agreement-after-three-years-of-negotiations 2025-04-17T22:03:46+00:00 hourly 0.9 https://trial.medpath.com/news/cdc-advisory-panel-recommends-expanded-rsv-vaccination-for-adults-50-59-with-high-risk-conditions 2025-04-17T21:06:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdc-advisory-panel-recommends-expanded-rsv-vaccination-for-adults-50-59-with-high-risk-conditions 2025-04-17T21:06:13+00:00 hourly 0.9 https://trial.medpath.com/news/avita-medical-reports-67-revenue-growth-in-q1-2025-expands-product-portfolio 2025-04-17T20:58:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avita-medical-reports-67-revenue-growth-in-q1-2025-expands-product-portfolio 2025-04-17T20:58:26+00:00 hourly 0.9 https://trial.medpath.com/news/brisk-walking-significantly-reduces-risk-of-heart-rhythm-disorders-new-study-finds 2025-04-17T20:41:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brisk-walking-significantly-reduces-risk-of-heart-rhythm-disorders-new-study-finds 2025-04-17T20:41:28+00:00 hourly 0.9 https://trial.medpath.com/news/new-studies-reveal-menopause-often-begins-earlier-than-most-women-expect 2025-04-17T20:39:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-studies-reveal-menopause-often-begins-earlier-than-most-women-expect 2025-04-17T20:39:42+00:00 hourly 0.9 https://trial.medpath.com/news/dr-mehmet-oz-confirmed-as-head-of-centers-for-medicare-medicaid-services 2025-04-17T20:39:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dr-mehmet-oz-confirmed-as-head-of-centers-for-medicare-medicaid-services 2025-04-17T20:39:26+00:00 hourly 0.9 https://trial.medpath.com/news/modern-approaches-to-joint-replacement-recovery-faster-healing-less-pain 2025-04-17T20:37:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/modern-approaches-to-joint-replacement-recovery-faster-healing-less-pain 2025-04-17T20:37:59+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-drug-use-surges-among-type-1-diabetes-patients-despite-safety-concerns 2025-04-17T20:36:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-drug-use-surges-among-type-1-diabetes-patients-despite-safety-concerns 2025-04-17T20:36:15+00:00 hourly 0.9 https://trial.medpath.com/news/smartwatch-innovation-new-heart-rate-to-step-ratio-emerges-as-superior-health-indicator 2025-04-17T20:36:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/smartwatch-innovation-new-heart-rate-to-step-ratio-emerges-as-superior-health-indicator 2025-04-17T20:36:11+00:00 hourly 0.9 https://trial.medpath.com/news/trump-nominates-susan-monarez-as-permanent-cdc-director-after-weldon-withdrawal 2025-04-17T20:35:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-nominates-susan-monarez-as-permanent-cdc-director-after-weldon-withdrawal 2025-04-17T20:35:07+00:00 hourly 0.9 https://trial.medpath.com/news/global-surge-in-early-onset-colorectal-cancer-demands-urgent-attention 2025-04-17T20:34:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-surge-in-early-onset-colorectal-cancer-demands-urgent-attention 2025-04-17T20:34:55+00:00 hourly 0.9 https://trial.medpath.com/news/novel-screening-methods-show-promise-for-early-detection-of-cognitive-decline 2025-04-17T20:34:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-screening-methods-show-promise-for-early-detection-of-cognitive-decline 2025-04-17T20:34:42+00:00 hourly 0.9 https://trial.medpath.com/news/racial-disparities-in-ca-125-testing-may-delay-ovarian-cancer-treatment-for-black-and-native-american-women 2025-04-17T20:34:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/racial-disparities-in-ca-125-testing-may-delay-ovarian-cancer-treatment-for-black-and-native-american-women 2025-04-17T20:34:40+00:00 hourly 0.9 https://trial.medpath.com/news/fda-launches-operation-stork-speed-to-modernize-infant-formula-safety-and-nutrition-standards 2025-04-17T20:33:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-launches-operation-stork-speed-to-modernize-infant-formula-safety-and-nutrition-standards 2025-04-17T20:33:55+00:00 hourly 0.9 https://trial.medpath.com/news/measles-outbreak-spreads-across-multiple-states-with-two-fatalities-reported 2025-04-17T20:33:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/measles-outbreak-spreads-across-multiple-states-with-two-fatalities-reported 2025-04-17T20:33:15+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-warning-on-rising-nitrous-oxide-misuse-injuries-as-recreational-products-flood-market 2025-04-17T20:32:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-warning-on-rising-nitrous-oxide-misuse-injuries-as-recreational-products-flood-market 2025-04-17T20:32:55+00:00 hourly 0.9 https://trial.medpath.com/news/hhs-terminates-funding-for-geovax-s-next-generation-covid-19-vaccine-amid-ongoing-clinical-trials 2025-04-17T20:12:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hhs-terminates-funding-for-geovax-s-next-generation-covid-19-vaccine-amid-ongoing-clinical-trials 2025-04-17T20:12:10+00:00 hourly 0.9 https://trial.medpath.com/news/cannabis-use-during-pregnancy-linked-to-tripled-risk-of-behavioral-disorders-in-children 2025-04-17T20:09:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cannabis-use-during-pregnancy-linked-to-tripled-risk-of-behavioral-disorders-in-children 2025-04-17T20:09:48+00:00 hourly 0.9 https://trial.medpath.com/news/ai-model-successfully-predicts-cognitive-decline-in-menopausal-women 2025-04-17T20:08:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-model-successfully-predicts-cognitive-decline-in-menopausal-women 2025-04-17T20:08:56+00:00 hourly 0.9 https://trial.medpath.com/news/anti-inflammatory-drugs-and-infection-control-may-reduce-dementia-risk-studies-suggest 2025-04-17T20:08:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anti-inflammatory-drugs-and-infection-control-may-reduce-dementia-risk-studies-suggest 2025-04-17T20:08:15+00:00 hourly 0.9 https://trial.medpath.com/news/utah-becomes-first-state-to-ban-fluoride-in-public-water-systems 2025-04-17T20:07:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/utah-becomes-first-state-to-ban-fluoride-in-public-water-systems 2025-04-17T20:07:13+00:00 hourly 0.9 https://trial.medpath.com/news/young-smokers-face-double-the-risk-of-unexplained-strokes-study-reveals 2025-04-17T20:05:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/young-smokers-face-double-the-risk-of-unexplained-strokes-study-reveals 2025-04-17T20:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/environmental-pollutants-significantly-increase-childhood-asthma-risk-new-studies-reveal 2025-04-17T20:05:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/environmental-pollutants-significantly-increase-childhood-asthma-risk-new-studies-reveal 2025-04-17T20:05:55+00:00 hourly 0.9 https://trial.medpath.com/news/measles-outbreak-in-west-texas-escalates-to-58-cases-amid-low-vaccination-rates 2025-04-17T20:04:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/measles-outbreak-in-west-texas-escalates-to-58-cases-amid-low-vaccination-rates 2025-04-17T20:04:05+00:00 hourly 0.9 https://trial.medpath.com/news/antidepressants-linked-to-increased-risk-of-sudden-cardiac-death-danish-study-reveals 2025-04-17T20:04:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/antidepressants-linked-to-increased-risk-of-sudden-cardiac-death-danish-study-reveals 2025-04-17T20:04:03+00:00 hourly 0.9 https://trial.medpath.com/news/hormonal-contraceptives-and-hrt-linked-to-increased-cardiovascular-risks-in-women 2025-04-17T20:03:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hormonal-contraceptives-and-hrt-linked-to-increased-cardiovascular-risks-in-women 2025-04-17T20:03:56+00:00 hourly 0.9 https://trial.medpath.com/news/wildfire-smoke-exposure-linked-to-prolonged-cardiovascular-and-respiratory-health-risks 2025-04-17T20:02:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wildfire-smoke-exposure-linked-to-prolonged-cardiovascular-and-respiratory-health-risks 2025-04-17T20:02:14+00:00 hourly 0.9 https://trial.medpath.com/news/roche-adjusts-tominersen-dosing-in-generation-hd2-trial-for-huntington-s-disease 2025-04-17T19:52:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-adjusts-tominersen-dosing-in-generation-hd2-trial-for-huntington-s-disease 2025-04-17T19:52:06+00:00 hourly 0.9 https://trial.medpath.com/news/pregnancy-complications-linked-to-increased-heart-disease-risk-in-women-and-their-sisters 2025-04-17T19:47:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pregnancy-complications-linked-to-increased-heart-disease-risk-in-women-and-their-sisters 2025-04-17T19:47:14+00:00 hourly 0.9 https://trial.medpath.com/news/federal-judge-orders-cdc-and-fda-to-restore-public-health-websites-removed-under-trump-administration 2025-04-17T19:47:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-judge-orders-cdc-and-fda-to-restore-public-health-websites-removed-under-trump-administration 2025-04-17T19:47:06+00:00 hourly 0.9 https://trial.medpath.com/news/h5n1-bird-flu-may-spread-through-airborne-transmission-czech-study-reveals 2025-04-17T19:47:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/h5n1-bird-flu-may-spread-through-airborne-transmission-czech-study-reveals 2025-04-17T19:47:01+00:00 hourly 0.9 https://trial.medpath.com/news/low-ldl-cholesterol-levels-associated-with-reduced-dementia-and-alzheimer-s-risk 2025-04-17T19:46:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/low-ldl-cholesterol-levels-associated-with-reduced-dementia-and-alzheimer-s-risk 2025-04-17T19:46:08+00:00 hourly 0.9 https://trial.medpath.com/news/covid-19-continues-to-pose-greater-health-threat-than-flu-and-rsv-study-finds 2025-04-17T19:45:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/covid-19-continues-to-pose-greater-health-threat-than-flu-and-rsv-study-finds 2025-04-17T19:45:55+00:00 hourly 0.9 https://trial.medpath.com/news/bariatric-surgery-in-adolescents-shows-superior-long-term-health-benefits-compared-to-adults 2025-04-17T19:45:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bariatric-surgery-in-adolescents-shows-superior-long-term-health-benefits-compared-to-adults 2025-04-17T19:45:19+00:00 hourly 0.9 https://trial.medpath.com/news/alarming-gap-in-dementia-diagnosis-awareness-reveals-healthcare-disparities 2025-04-17T19:43:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alarming-gap-in-dementia-diagnosis-awareness-reveals-healthcare-disparities 2025-04-17T19:43:16+00:00 hourly 0.9 https://trial.medpath.com/news/adhd-persists-in-adults-with-autism-at-rates-similar-to-childhood-study-finds 2025-04-17T19:43:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adhd-persists-in-adults-with-autism-at-rates-similar-to-childhood-study-finds 2025-04-17T19:43:15+00:00 hourly 0.9 https://trial.medpath.com/news/ketamine-use-surges-40-in-u-s-as-medical-authorities-call-for-stricter-controls 2025-04-17T19:43:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ketamine-use-surges-40-in-u-s-as-medical-authorities-call-for-stricter-controls 2025-04-17T19:43:09+00:00 hourly 0.9 https://trial.medpath.com/news/menthol-cigarette-bans-drive-smokers-toward-cessation-therapies-rather-than-alternative-tobacco-products 2025-04-17T19:43:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/menthol-cigarette-bans-drive-smokers-toward-cessation-therapies-rather-than-alternative-tobacco-products 2025-04-17T19:43:04+00:00 hourly 0.9 https://trial.medpath.com/news/frequent-antibiotic-use-in-early-childhood-linked-to-higher-asthma-and-allergy-risk 2025-04-17T19:43:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/frequent-antibiotic-use-in-early-childhood-linked-to-higher-asthma-and-allergy-risk 2025-04-17T19:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-unveils-new-front-of-package-food-labels-to-combat-chronic-disease-epidemic 2025-04-17T19:41:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-unveils-new-front-of-package-food-labels-to-combat-chronic-disease-epidemic 2025-04-17T19:41:27+00:00 hourly 0.9 https://trial.medpath.com/news/poor-sleep-quality-significantly-impacts-workplace-productivity-new-research-reveals 2025-04-17T19:40:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/poor-sleep-quality-significantly-impacts-workplace-productivity-new-research-reveals 2025-04-17T19:40:04+00:00 hourly 0.9 https://trial.medpath.com/news/exercise-significantly-reduces-cancer-mortality-risk-new-studies-confirm 2025-04-17T19:39:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exercise-significantly-reduces-cancer-mortality-risk-new-studies-confirm 2025-04-17T19:39:45+00:00 hourly 0.9 https://trial.medpath.com/news/hsv-1-infection-linked-to-80-increased-alzheimer-s-risk-in-large-scale-claims-analysis 2025-04-17T19:39:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hsv-1-infection-linked-to-80-increased-alzheimer-s-risk-in-large-scale-claims-analysis 2025-04-17T19:39:28+00:00 hourly 0.9 https://trial.medpath.com/news/morning-coffee-consumption-linked-to-reduced-cardiovascular-death-risk-and-healthy-aging-in-women 2025-04-17T19:39:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/morning-coffee-consumption-linked-to-reduced-cardiovascular-death-risk-and-healthy-aging-in-women 2025-04-17T19:39:24+00:00 hourly 0.9 https://trial.medpath.com/news/bilingualism-boosts-cognitive-function-in-children-with-autism-new-research-finds 2025-04-17T19:38:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bilingualism-boosts-cognitive-function-in-children-with-autism-new-research-finds 2025-04-17T19:38:57+00:00 hourly 0.9 https://trial.medpath.com/news/early-physical-therapy-within-two-months-critical-for-concussion-recovery-clinical-trial-reveals 2025-04-17T19:38:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/early-physical-therapy-within-two-months-critical-for-concussion-recovery-clinical-trial-reveals 2025-04-17T19:38:03+00:00 hourly 0.9 https://trial.medpath.com/news/bird-flu-outbreak-linked-to-raw-pet-foods-prompts-multiple-recalls-across-us 2025-04-17T19:36:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bird-flu-outbreak-linked-to-raw-pet-foods-prompts-multiple-recalls-across-us 2025-04-17T19:36:10+00:00 hourly 0.9 https://trial.medpath.com/news/ai-advances-in-breast-cancer-detection-new-technologies-show-promise-for-earlier-diagnosis 2025-04-17T19:36:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-advances-in-breast-cancer-detection-new-technologies-show-promise-for-earlier-diagnosis 2025-04-17T19:36:06+00:00 hourly 0.9 https://trial.medpath.com/news/dance-therapy-shows-promising-results-for-parkinson-s-and-alzheimer-s-patients 2025-04-17T19:36:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dance-therapy-shows-promising-results-for-parkinson-s-and-alzheimer-s-patients 2025-04-17T19:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/norovirus-outbreaks-on-cruise-ships-intensify-one-death-reported-amid-rising-cases 2025-04-17T19:35:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/norovirus-outbreaks-on-cruise-ships-intensify-one-death-reported-amid-rising-cases 2025-04-17T19:35:21+00:00 hourly 0.9 https://trial.medpath.com/news/cdc-confirms-concerning-mutations-in-first-severe-u-s-bird-flu-case 2025-04-17T19:34:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdc-confirms-concerning-mutations-in-first-severe-u-s-bird-flu-case 2025-04-17T19:34:28+00:00 hourly 0.9 https://trial.medpath.com/news/team-sports-enhance-cognitive-development-and-academic-success-in-children-studies-show 2025-04-17T19:34:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/team-sports-enhance-cognitive-development-and-academic-success-in-children-studies-show 2025-04-17T19:34:21+00:00 hourly 0.9 https://trial.medpath.com/news/air-pollution-during-pregnancy-linked-to-severe-neonatal-health-risks-and-brain-development-issues 2025-04-17T19:34:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/air-pollution-during-pregnancy-linked-to-severe-neonatal-health-risks-and-brain-development-issues 2025-04-17T19:34:13+00:00 hourly 0.9 https://trial.medpath.com/news/omega-3-fatty-acids-show-promise-in-slowing-prostate-cancer-progression 2025-04-17T19:34:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/omega-3-fatty-acids-show-promise-in-slowing-prostate-cancer-progression 2025-04-17T19:34:12+00:00 hourly 0.9 https://trial.medpath.com/news/u-s-life-expectancy-rebounds-as-overdose-deaths-decline-for-first-time-in-a-decade 2025-04-17T19:33:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/u-s-life-expectancy-rebounds-as-overdose-deaths-decline-for-first-time-in-a-decade 2025-04-17T19:33:23+00:00 hourly 0.9 https://trial.medpath.com/news/fda-proposes-historic-nicotine-reduction-in-tobacco-products-to-combat-addiction 2025-04-17T19:33:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-proposes-historic-nicotine-reduction-in-tobacco-products-to-combat-addiction 2025-04-17T19:33:20+00:00 hourly 0.9 https://trial.medpath.com/news/pediatric-flu-deaths-reach-highest-level-since-2009-as-vaccination-rates-decline 2025-04-17T19:33:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pediatric-flu-deaths-reach-highest-level-since-2009-as-vaccination-rates-decline 2025-04-17T19:33:19+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-effective-strategies-for-young-adults-quitting-vaping 2025-04-17T19:33:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-effective-strategies-for-young-adults-quitting-vaping 2025-04-17T19:33:15+00:00 hourly 0.9 https://trial.medpath.com/news/hpv-self-testing-proves-effective-for-cervical-cancer-screening-new-study-confirms 2025-04-17T19:32:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hpv-self-testing-proves-effective-for-cervical-cancer-screening-new-study-confirms 2025-04-17T19:32:43+00:00 hourly 0.9 https://trial.medpath.com/news/malaria-suspected-in-deadly-congo-outbreak-as-laboratory-tests-show-positive-results 2025-04-17T19:32:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/malaria-suspected-in-deadly-congo-outbreak-as-laboratory-tests-show-positive-results 2025-04-17T19:32:15+00:00 hourly 0.9 https://trial.medpath.com/news/dual-use-of-cigarettes-and-e-cigarettes-undermines-smoking-cessation-and-increases-health-risks 2025-04-17T19:31:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dual-use-of-cigarettes-and-e-cigarettes-undermines-smoking-cessation-and-increases-health-risks 2025-04-17T19:31:57+00:00 hourly 0.9 https://trial.medpath.com/news/physical-fitness-linked-to-better-cognitive-health-in-older-adults-studies-show 2025-04-17T19:31:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/physical-fitness-linked-to-better-cognitive-health-in-older-adults-studies-show 2025-04-17T19:31:47+00:00 hourly 0.9 https://trial.medpath.com/news/salmonella-outbreak-linked-to-mexican-cucumbers-expands-to-100-cases-across-23-states 2025-04-17T19:31:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/salmonella-outbreak-linked-to-mexican-cucumbers-expands-to-100-cases-across-23-states 2025-04-17T19:31:35+00:00 hourly 0.9 https://trial.medpath.com/news/socioeconomic-factors-and-parental-smoking-linked-to-worse-ms-outcomes-in-children 2025-04-17T19:31:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/socioeconomic-factors-and-parental-smoking-linked-to-worse-ms-outcomes-in-children 2025-04-17T19:31:29+00:00 hourly 0.9 https://trial.medpath.com/news/preterm-birth-linked-to-lifelong-socioeconomic-and-health-disadvantages-studies-reveal 2025-04-17T19:31:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/preterm-birth-linked-to-lifelong-socioeconomic-and-health-disadvantages-studies-reveal 2025-04-17T19:31:27+00:00 hourly 0.9 https://trial.medpath.com/news/wildfire-smoke-exposure-linked-to-increased-dementia-and-mental-health-risks-studies-find 2025-04-17T19:31:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wildfire-smoke-exposure-linked-to-increased-dementia-and-mental-health-risks-studies-find 2025-04-17T19:31:06+00:00 hourly 0.9 https://trial.medpath.com/news/e-coli-contamination-prompts-massive-recall-of-167000-pounds-of-ground-beef 2025-04-17T19:30:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/e-coli-contamination-prompts-massive-recall-of-167000-pounds-of-ground-beef 2025-04-17T19:30:57+00:00 hourly 0.9 https://trial.medpath.com/news/thermo-fisher-scientific-launches-first-us-cell-therapy-collaboration-center-in-california 2025-04-17T19:20:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thermo-fisher-scientific-launches-first-us-cell-therapy-collaboration-center-in-california 2025-04-17T19:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/alcohol-related-deaths-and-cancer-fatalities-surge-in-u-s-over-past-two-decades 2025-04-17T19:05:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alcohol-related-deaths-and-cancer-fatalities-surge-in-u-s-over-past-two-decades 2025-04-17T19:05:10+00:00 hourly 0.9 https://trial.medpath.com/news/global-obesity-crisis-accelerating-80-of-americans-projected-to-be-overweight-or-obese-by-2050 2025-04-17T19:04:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-obesity-crisis-accelerating-80-of-americans-projected-to-be-overweight-or-obese-by-2050 2025-04-17T19:04:55+00:00 hourly 0.9 https://trial.medpath.com/news/excessive-sedentary-time-linked-to-increased-cardiovascular-risk-even-in-active-individuals 2025-04-17T19:04:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/excessive-sedentary-time-linked-to-increased-cardiovascular-risk-even-in-active-individuals 2025-04-17T19:04:54+00:00 hourly 0.9 https://trial.medpath.com/news/canadian-teen-s-critical-bird-flu-case-raises-alarm-as-h5n1-infections-spread 2025-04-17T19:04:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/canadian-teen-s-critical-bird-flu-case-raises-alarm-as-h5n1-infections-spread 2025-04-17T19:04:37+00:00 hourly 0.9 https://trial.medpath.com/news/adequate-sleep-significantly-reduces-hypertension-risk-in-adolescents-new-research-confirms 2025-04-17T19:04:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adequate-sleep-significantly-reduces-hypertension-risk-in-adolescents-new-research-confirms 2025-04-17T19:04:32+00:00 hourly 0.9 https://trial.medpath.com/news/obesity-related-cancer-deaths-more-than-triple-in-u-s-over-two-decades 2025-04-17T19:04:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/obesity-related-cancer-deaths-more-than-triple-in-u-s-over-two-decades 2025-04-17T19:04:13+00:00 hourly 0.9 https://trial.medpath.com/news/study-confirms-immediate-cpr-saves-lives-regardless-of-provider-training 2025-04-17T19:04:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-confirms-immediate-cpr-saves-lives-regardless-of-provider-training 2025-04-17T19:04:10+00:00 hourly 0.9 https://trial.medpath.com/news/ai-powered-analysis-reveals-long-covid-affects-nearly-23-of-americans-higher-than-previous-estimates 2025-04-17T19:04:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-powered-analysis-reveals-long-covid-affects-nearly-23-of-americans-higher-than-previous-estimates 2025-04-17T19:04:03+00:00 hourly 0.9 https://trial.medpath.com/news/sleep-disruptions-emerge-as-critical-early-indicators-of-alzheimer-s-disease-risk 2025-04-17T19:03:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sleep-disruptions-emerge-as-critical-early-indicators-of-alzheimer-s-disease-risk 2025-04-17T19:03:56+00:00 hourly 0.9 https://trial.medpath.com/news/maternal-vitamin-d-levels-during-early-pregnancy-significantly-impact-infant-health-outcomes 2025-04-17T19:03:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maternal-vitamin-d-levels-during-early-pregnancy-significantly-impact-infant-health-outcomes 2025-04-17T19:03:52+00:00 hourly 0.9 https://trial.medpath.com/news/whooping-cough-cases-surge-sixfold-in-the-u-s-reaching-highest-levels-since-2014 2025-04-17T19:03:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/whooping-cough-cases-surge-sixfold-in-the-u-s-reaching-highest-levels-since-2014 2025-04-17T19:03:16+00:00 hourly 0.9 https://trial.medpath.com/news/h5n1-bird-flu-detected-in-u-s-pig-for-first-time-raising-transmission-concerns 2025-04-17T19:03:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/h5n1-bird-flu-detected-in-u-s-pig-for-first-time-raising-transmission-concerns 2025-04-17T19:03:10+00:00 hourly 0.9 https://trial.medpath.com/news/health-insurance-gaps-lead-to-later-cancer-diagnoses-among-black-and-hispanic-americans 2025-04-17T19:03:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-insurance-gaps-lead-to-later-cancer-diagnoses-among-black-and-hispanic-americans 2025-04-17T19:03:08+00:00 hourly 0.9 https://trial.medpath.com/news/concussions-in-hockey-players-linked-to-doubled-risk-of-depression-and-tripled-risk-of-burnout 2025-04-17T19:02:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/concussions-in-hockey-players-linked-to-doubled-risk-of-depression-and-tripled-risk-of-burnout 2025-04-17T19:02:32+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-medications-reshape-obesity-treatment-landscape-as-bariatric-surgeries-decline-25 2025-04-17T19:02:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-medications-reshape-obesity-treatment-landscape-as-bariatric-surgeries-decline-25 2025-04-17T19:02:24+00:00 hourly 0.9 https://trial.medpath.com/news/cdc-reports-second-missouri-bird-flu-case-without-animal-exposure-as-u-s-total-reaches-67 2025-04-17T19:02:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdc-reports-second-missouri-bird-flu-case-without-animal-exposure-as-u-s-total-reaches-67 2025-04-17T19:02:21+00:00 hourly 0.9 https://trial.medpath.com/news/expanded-glp-1-drug-access-could-save-42000-lives-and-billions-in-healthcare-costs-annually 2025-04-17T19:01:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/expanded-glp-1-drug-access-could-save-42000-lives-and-billions-in-healthcare-costs-annually 2025-04-17T19:01:39+00:00 hourly 0.9 https://trial.medpath.com/news/infant-mortality-rises-in-states-with-abortion-bans-new-jama-studies-reveal 2025-04-17T19:01:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/infant-mortality-rises-in-states-with-abortion-bans-new-jama-studies-reveal 2025-04-17T19:01:29+00:00 hourly 0.9 https://trial.medpath.com/news/election-related-stress-reaches-critical-levels-among-americans-apa-survey-reveals 2025-04-17T19:01:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/election-related-stress-reaches-critical-levels-among-americans-apa-survey-reveals 2025-04-17T19:01:27+00:00 hourly 0.9 https://trial.medpath.com/news/taylor-farms-recalls-onions-linked-to-deadly-e-coli-outbreak-in-mcdonald-s-quarter-pounders 2025-04-17T19:01:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/taylor-farms-recalls-onions-linked-to-deadly-e-coli-outbreak-in-mcdonald-s-quarter-pounders 2025-04-17T19:01:25+00:00 hourly 0.9 https://trial.medpath.com/news/pfas-forever-chemicals-contaminate-drinking-water-for-75-95-million-americans-usgs-study-reveals 2025-04-17T19:00:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfas-forever-chemicals-contaminate-drinking-water-for-75-95-million-americans-usgs-study-reveals 2025-04-17T19:00:59+00:00 hourly 0.9 https://trial.medpath.com/news/physical-activity-in-childhood-linked-to-better-mental-health-and-cognitive-function-in-adolescence 2025-04-17T19:00:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/physical-activity-in-childhood-linked-to-better-mental-health-and-cognitive-function-in-adolescence 2025-04-17T19:00:53+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-510-k-clearance-to-bvi-medical-s-novel-laser-system-for-glaucoma-treatment 2025-04-17T18:37:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-510-k-clearance-to-bvi-medical-s-novel-laser-system-for-glaucoma-treatment 2025-04-17T18:37:05+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-25-first-time-generic-drugs-in-first-half-of-2025-expanding-access-to-critical-therapies 2025-04-17T18:31:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-25-first-time-generic-drugs-in-first-half-of-2025-expanding-access-to-critical-therapies 2025-04-17T18:31:19+00:00 hourly 0.9 https://trial.medpath.com/news/probiogen-s-glymaxx-technology-powers-commercially-available-her2-biliary-cancer-treatment 2025-04-17T17:35:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/probiogen-s-glymaxx-technology-powers-commercially-available-her2-biliary-cancer-treatment 2025-04-17T17:35:54+00:00 hourly 0.9 https://trial.medpath.com/news/galmed-s-aramchol-shows-promising-results-in-enhancing-regorafenib-s-efficacy-against-gi-cancers 2025-04-17T17:35:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galmed-s-aramchol-shows-promising-results-in-enhancing-regorafenib-s-efficacy-against-gi-cancers 2025-04-17T17:35:11+00:00 hourly 0.9 https://trial.medpath.com/news/sol-gel-and-mayne-pharma-announce-16-million-deal-for-epsolay-and-twyneo-rights-in-the-u-s 2025-04-17T17:03:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sol-gel-and-mayne-pharma-announce-16-million-deal-for-epsolay-and-twyneo-rights-in-the-u-s 2025-04-17T17:03:10+00:00 hourly 0.9 https://trial.medpath.com/news/trump-s-executive-order-delays-medicare-drug-price-negotiations-sparking-industry-and-policy-debate 2025-04-17T15:33:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-s-executive-order-delays-medicare-drug-price-negotiations-sparking-industry-and-policy-debate 2025-04-17T15:33:16+00:00 hourly 0.9 https://trial.medpath.com/news/ligand-s-pelthos-therapeutics-to-merge-with-channel-therapeutics-in-50m-deal-focused-on-molluscum-treatment 2025-04-17T15:33:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ligand-s-pelthos-therapeutics-to-merge-with-channel-therapeutics-in-50m-deal-focused-on-molluscum-treatment 2025-04-17T15:33:12+00:00 hourly 0.9 https://trial.medpath.com/news/channel-therapeutics-and-pelthos-therapeutics-merge-to-accelerate-zelsuvmi-launch-for-molluscum-contagiosum 2025-04-17T15:33:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/channel-therapeutics-and-pelthos-therapeutics-merge-to-accelerate-zelsuvmi-launch-for-molluscum-contagiosum 2025-04-17T15:33:10+00:00 hourly 0.9 https://trial.medpath.com/news/dasatinib-plus-car-t-cell-therapy-achieves-85-complete-molecular-remission-in-newly-diagnosed-ph-all 2025-04-17T15:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dasatinib-plus-car-t-cell-therapy-achieves-85-complete-molecular-remission-in-newly-diagnosed-ph-all 2025-04-17T15:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/alembic-pharmaceuticals-secures-usfda-approvals-for-carbamazepine-and-amlodipine-atorvastatin-generics 2025-04-17T14:49:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alembic-pharmaceuticals-secures-usfda-approvals-for-carbamazepine-and-amlodipine-atorvastatin-generics 2025-04-17T14:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/trodelvy-keytruda-combination-shows-promising-results-in-first-line-treatment-for-triple-negative-breast-cancer 2025-04-17T14:32:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trodelvy-keytruda-combination-shows-promising-results-in-first-line-treatment-for-triple-negative-breast-cancer 2025-04-17T14:32:16+00:00 hourly 0.9 https://trial.medpath.com/news/caliway-s-cbl-514-shows-promising-phase-2-results-for-dercum-s-disease-advancing-to-phase-2b-trial 2025-04-17T14:03:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caliway-s-cbl-514-shows-promising-phase-2-results-for-dercum-s-disease-advancing-to-phase-2b-trial 2025-04-17T14:03:12+00:00 hourly 0.9 https://trial.medpath.com/news/india-bans-35-unapproved-fixed-dose-combination-drugs-over-safety-concerns 2025-04-17T14:03:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-bans-35-unapproved-fixed-dose-combination-drugs-over-safety-concerns 2025-04-17T14:03:09+00:00 hourly 0.9 https://trial.medpath.com/news/3d-pathology-technology-reclassifies-67-of-her2-null-breast-cancer-cases-as-her2-expressing 2025-04-17T12:29:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/3d-pathology-technology-reclassifies-67-of-her2-null-breast-cancer-cases-as-her2-expressing 2025-04-17T12:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/diabetes-drug-metformin-shows-promise-in-preventing-acute-myeloid-leukemia 2025-04-17T11:06:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/diabetes-drug-metformin-shows-promise-in-preventing-acute-myeloid-leukemia 2025-04-17T11:06:17+00:00 hourly 0.9 https://trial.medpath.com/news/solo-pace-receives-fda-clearance-for-novel-tavr-pacing-system-with-first-successful-human-procedures 2025-04-17T10:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/solo-pace-receives-fda-clearance-for-novel-tavr-pacing-system-with-first-successful-human-procedures 2025-04-17T10:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-medline-s-reflex-hybrid-nitinol-implants-for-foot-and-ankle-surgery 2025-04-17T09:06:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-medline-s-reflex-hybrid-nitinol-implants-for-foot-and-ankle-surgery 2025-04-17T09:06:28+00:00 hourly 0.9 https://trial.medpath.com/news/glenmark-to-launch-generic-adderall-in-may-2025-amid-ongoing-shortage 2025-04-17T09:06:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glenmark-to-launch-generic-adderall-in-may-2025-amid-ongoing-shortage 2025-04-17T09:06:26+00:00 hourly 0.9 https://trial.medpath.com/news/design-therapeutics-appoints-dr-chris-storgard-as-chief-medical-officer-to-advance-genetac-r-pipeline 2025-04-17T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/design-therapeutics-appoints-dr-chris-storgard-as-chief-medical-officer-to-advance-genetac-r-pipeline 2025-04-17T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-commits-1-3-billion-to-verve-therapeutics-cardiovascular-gene-therapy-platform 2025-04-17T06:35:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-commits-1-3-billion-to-verve-therapeutics-cardiovascular-gene-therapy-platform 2025-04-17T06:35:41+00:00 hourly 0.9 https://trial.medpath.com/news/porton-advanced-accelerates-development-of-innovative-cell-therapies-for-solid-tumors-with-key-partnerships 2025-04-17T06:35:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/porton-advanced-accelerates-development-of-innovative-cell-therapies-for-solid-tumors-with-key-partnerships 2025-04-17T06:35:35+00:00 hourly 0.9 https://trial.medpath.com/news/iga-nephropathy-pipeline-shows-robust-growth-with-30-therapies-in-development 2025-04-17T06:35:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iga-nephropathy-pipeline-shows-robust-growth-with-30-therapies-in-development 2025-04-17T06:35:30+00:00 hourly 0.9 https://trial.medpath.com/news/sabin-launches-u-s-phase-2-trial-for-marburg-vaccine-amid-rising-global-outbreaks 2025-04-17T06:35:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sabin-launches-u-s-phase-2-trial-for-marburg-vaccine-amid-rising-global-outbreaks 2025-04-17T06:35:17+00:00 hourly 0.9 https://trial.medpath.com/news/podo-therapeutics-advances-cancer-precision-medicine-with-novel-organoid-immune-cell-co-culture-platform 2025-04-17T06:35:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/podo-therapeutics-advances-cancer-precision-medicine-with-novel-organoid-immune-cell-co-culture-platform 2025-04-17T06:35:09+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-secures-fda-approval-for-nubeqa-in-metastatic-prostate-cancer-targeting-eur3-billion-peak-sales 2025-04-17T05:36:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-secures-fda-approval-for-nubeqa-in-metastatic-prostate-cancer-targeting-eur3-billion-peak-sales 2025-04-17T05:36:02+00:00 hourly 0.9 https://trial.medpath.com/news/yunu-secures-oversubscribed-funding-to-transform-clinical-trial-imaging-workflows 2025-04-17T05:02:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/yunu-secures-oversubscribed-funding-to-transform-clinical-trial-imaging-workflows 2025-04-17T05:02:58+00:00 hourly 0.9 https://trial.medpath.com/news/sonrai-and-paige-partner-to-accelerate-precision-medicine-r-d-with-advanced-ai-capabilities 2025-04-17T02:04:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sonrai-and-paige-partner-to-accelerate-precision-medicine-r-d-with-advanced-ai-capabilities 2025-04-17T02:04:29+00:00 hourly 0.9 https://trial.medpath.com/news/global-regulatory-landscape-for-psoriasis-and-pompe-disease-treatments-evolving-in-2025 2025-04-17T02:04:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-regulatory-landscape-for-psoriasis-and-pompe-disease-treatments-evolving-in-2025 2025-04-17T02:04:23+00:00 hourly 0.9 https://trial.medpath.com/news/sebiotic-r-probiotic-shows-96-efficacy-in-treating-drug-induced-constipation-in-clinical-trial 2025-04-17T01:40:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sebiotic-r-probiotic-shows-96-efficacy-in-treating-drug-induced-constipation-in-clinical-trial 2025-04-17T01:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/biosidus-reports-positive-phase-iii-interim-results-for-agalsidase-beta-biosimilar-in-fabry-disease 2025-04-17T00:32:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biosidus-reports-positive-phase-iii-interim-results-for-agalsidase-beta-biosimilar-in-fabry-disease 2025-04-17T00:32:57+00:00 hourly 0.9 https://trial.medpath.com/news/synaptixbio-selects-antisense-oligonucleotide-candidate-for-rare-disease-h-abc-clinical-trials 2025-04-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/synaptixbio-selects-antisense-oligonucleotide-candidate-for-rare-disease-h-abc-clinical-trials 2025-04-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/verrica-pharmaceuticals-reports-record-growth-in-ycanth-r-dispensed-units-for-molluscum-contagiosum-treatment 2025-04-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verrica-pharmaceuticals-reports-record-growth-in-ycanth-r-dispensed-units-for-molluscum-contagiosum-treatment 2025-04-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/mark-cuban-s-cost-plus-drug-company-partners-with-morris-dickson-to-address-injectable-medication-shortages 2025-04-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mark-cuban-s-cost-plus-drug-company-partners-with-morris-dickson-to-address-injectable-medication-shortages 2025-04-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-rehires-key-pharma-user-fee-negotiators-after-mass-layoffs-threaten-drug-review-process 2025-04-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-rehires-key-pharma-user-fee-negotiators-after-mass-layoffs-threaten-drug-review-process 2025-04-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/amt-medical-secures-25m-series-b-to-transform-coronary-bypass-surgery-with-minimally-invasive-technology 2025-04-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amt-medical-secures-25m-series-b-to-transform-coronary-bypass-surgery-with-minimally-invasive-technology 2025-04-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/new-report-reveals-trends-in-pharmaceutical-and-biotechnology-asset-purchase-deals-from-2019-2025 2025-04-16T23:04:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-report-reveals-trends-in-pharmaceutical-and-biotechnology-asset-purchase-deals-from-2019-2025 2025-04-16T23:04:07+00:00 hourly 0.9 https://trial.medpath.com/news/cullinan-therapeutics-advances-novel-cd19-t-cell-engager-to-phase-1-trial-for-rheumatoid-arthritis-in-europe 2025-04-16T23:03:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cullinan-therapeutics-advances-novel-cd19-t-cell-engager-to-phase-1-trial-for-rheumatoid-arthritis-in-europe 2025-04-16T23:03:42+00:00 hourly 0.9 https://trial.medpath.com/news/tlx101-shows-promising-survival-benefits-in-recurrent-high-grade-glioma-patients 2025-04-16T21:04:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tlx101-shows-promising-survival-benefits-in-recurrent-high-grade-glioma-patients 2025-04-16T21:04:01+00:00 hourly 0.9 https://trial.medpath.com/news/ingenu-cro-launches-pioneering-clinical-trials-for-idiopathic-hypersomnia-and-narcolepsy 2025-04-16T20:36:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ingenu-cro-launches-pioneering-clinical-trials-for-idiopathic-hypersomnia-and-narcolepsy 2025-04-16T20:36:27+00:00 hourly 0.9 https://trial.medpath.com/news/redhill-s-opaganib-shows-promise-for-weight-loss-and-diabetes-potentially-disrupting-100b-market 2025-04-16T20:03:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/redhill-s-opaganib-shows-promise-for-weight-loss-and-diabetes-potentially-disrupting-100b-market 2025-04-16T20:03:35+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-osilodrostat-isturisa-indication-for-broader-cushing-s-syndrome-treatment 2025-04-16T20:03:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-expands-osilodrostat-isturisa-indication-for-broader-cushing-s-syndrome-treatment 2025-04-16T20:03:19+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-scilex-s-liquid-colchicine-for-pericarditis-treatment 2025-04-16T20:03:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-scilex-s-liquid-colchicine-for-pericarditis-treatment 2025-04-16T20:03:15+00:00 hourly 0.9 https://trial.medpath.com/news/recursion-licenses-healthverity-s-real-world-data-to-transform-clinical-trial-design-and-analytics 2025-04-16T20:02:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recursion-licenses-healthverity-s-real-world-data-to-transform-clinical-trial-design-and-analytics 2025-04-16T20:02:58+00:00 hourly 0.9 https://trial.medpath.com/news/capricorn-scientific-and-florabio-partner-to-advance-animal-free-cell-culture-media-for-biotech-industry 2025-04-16T18:05:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/capricorn-scientific-and-florabio-partner-to-advance-animal-free-cell-culture-media-for-biotech-industry 2025-04-16T18:05:58+00:00 hourly 0.9 https://trial.medpath.com/news/mural-therapeutics-discontinues-nemvaleukin-program-and-cuts-90-of-workforce-following-clinical-setback 2025-04-16T17:34:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mural-therapeutics-discontinues-nemvaleukin-program-and-cuts-90-of-workforce-following-clinical-setback 2025-04-16T17:34:35+00:00 hourly 0.9 https://trial.medpath.com/news/nanostics-secures-cpsa-accreditation-for-relocated-prostate-cancer-diagnostic-lab-in-edmonton 2025-04-16T17:34:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanostics-secures-cpsa-accreditation-for-relocated-prostate-cancer-diagnostic-lab-in-edmonton 2025-04-16T17:34:33+00:00 hourly 0.9 https://trial.medpath.com/news/accent-therapeutics-initiates-phase-i-ii-trial-of-novel-kif18a-inhibitor-for-advanced-solid-tumors 2025-04-16T17:34:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/accent-therapeutics-initiates-phase-i-ii-trial-of-novel-kif18a-inhibitor-for-advanced-solid-tumors 2025-04-16T17:34:30+00:00 hourly 0.9 https://trial.medpath.com/news/cmg-pharmaceutical-secures-fda-approval-for-film-type-schizophrenia-treatment-mezofy 2025-04-16T17:34:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cmg-pharmaceutical-secures-fda-approval-for-film-type-schizophrenia-treatment-mezofy 2025-04-16T17:34:22+00:00 hourly 0.9 https://trial.medpath.com/news/aptar-launches-clinical-study-to-validate-smarttracktm-platform-for-accelerating-generic-inhaler-approvals 2025-04-16T17:34:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aptar-launches-clinical-study-to-validate-smarttracktm-platform-for-accelerating-generic-inhaler-approvals 2025-04-16T17:34:21+00:00 hourly 0.9 https://trial.medpath.com/news/abu-dhabi-partners-with-novartis-to-advance-genomics-research-and-precision-medicine 2025-04-16T17:34:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abu-dhabi-partners-with-novartis-to-advance-genomics-research-and-precision-medicine 2025-04-16T17:34:16+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-valtoco-nasal-spray-for-seizure-clusters-in-children-ages-2-5 2025-04-16T17:33:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-valtoco-nasal-spray-for-seizure-clusters-in-children-ages-2-5 2025-04-16T17:33:43+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-completes-first-surgeries-with-ottava-robotic-system-in-clinical-trial 2025-04-16T17:33:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-completes-first-surgeries-with-ottava-robotic-system-in-clinical-trial 2025-04-16T17:33:42+00:00 hourly 0.9 https://trial.medpath.com/news/clear-oasis-9-trial-colchicine-and-spironolactone-show-limited-benefits-after-myocardial-infarction 2025-04-16T17:33:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clear-oasis-9-trial-colchicine-and-spironolactone-show-limited-benefits-after-myocardial-infarction 2025-04-16T17:33:40+00:00 hourly 0.9 https://trial.medpath.com/news/oak-hill-bio-advances-rugonersen-for-angelman-syndrome-following-promising-phase-1-results-published-in-nature-medicine 2025-04-16T17:32:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oak-hill-bio-advances-rugonersen-for-angelman-syndrome-following-promising-phase-1-results-published-in-nature-medicine 2025-04-16T17:32:54+00:00 hourly 0.9 https://trial.medpath.com/news/machine-learning-models-using-systemic-inflammation-markers-predict-neoadjuvant-chemotherapy-response-in-breast-cancer 2025-04-16T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/machine-learning-models-using-systemic-inflammation-markers-predict-neoadjuvant-chemotherapy-response-in-breast-cancer 2025-04-16T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-ceo-david-ricks-tops-pharma-executive-compensation-at-29-2-million-in-2024 2025-04-16T15:24:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-ceo-david-ricks-tops-pharma-executive-compensation-at-29-2-million-in-2024 2025-04-16T15:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/glycomine-secures-115m-series-c-funding-to-advance-novel-treatment-for-pmm2-cdg-rare-disease 2025-04-16T15:05:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glycomine-secures-115m-series-c-funding-to-advance-novel-treatment-for-pmm2-cdg-rare-disease 2025-04-16T15:05:13+00:00 hourly 0.9 https://trial.medpath.com/news/msd-and-cyprumed-forge-493-million-deal-to-advance-oral-peptide-therapeutics 2025-04-16T14:33:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/msd-and-cyprumed-forge-493-million-deal-to-advance-oral-peptide-therapeutics 2025-04-16T14:33:04+00:00 hourly 0.9 https://trial.medpath.com/news/biovie-launches-sunrise-pd-trial-to-test-novel-anti-inflammatory-approach-for-early-parkinson-s-disease 2025-04-16T14:33:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biovie-launches-sunrise-pd-trial-to-test-novel-anti-inflammatory-approach-for-early-parkinson-s-disease 2025-04-16T14:33:01+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-significant-diagnostic-delays-for-minority-patients-with-generalized-myasthenia-gravis 2025-04-16T14:32:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-significant-diagnostic-delays-for-minority-patients-with-generalized-myasthenia-gravis 2025-04-16T14:32:56+00:00 hourly 0.9 https://trial.medpath.com/news/sglt2-inhibitors-demonstrate-significant-renal-benefits-in-heart-failure-and-chronic-kidney-disease 2025-04-16T14:32:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sglt2-inhibitors-demonstrate-significant-renal-benefits-in-heart-failure-and-chronic-kidney-disease 2025-04-16T14:32:53+00:00 hourly 0.9 https://trial.medpath.com/news/pgxai-launches-deneb-ai-model-to-revolutionize-drug-development-through-pharmacogenetics 2025-04-16T14:03:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pgxai-launches-deneb-ai-model-to-revolutionize-drug-development-through-pharmacogenetics 2025-04-16T14:03:56+00:00 hourly 0.9 https://trial.medpath.com/news/ritedose-doubles-vial-packaging-capacity-with-new-syntegon-line-to-support-ohtuvayre-copd-drug-production 2025-04-16T14:03:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ritedose-doubles-vial-packaging-capacity-with-new-syntegon-line-to-support-ohtuvayre-copd-drug-production 2025-04-16T14:03:54+00:00 hourly 0.9 https://trial.medpath.com/news/kras-inhibitors-market-set-to-exceed-2-billion-by-2030-with-next-generation-therapies-advancing 2025-04-16T14:03:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kras-inhibitors-market-set-to-exceed-2-billion-by-2030-with-next-generation-therapies-advancing 2025-04-16T14:03:53+00:00 hourly 0.9 https://trial.medpath.com/news/cellino-and-karis-bio-partner-to-develop-first-autologous-ipsc-therapy-for-cardiovascular-disease 2025-04-16T13:32:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellino-and-karis-bio-partner-to-develop-first-autologous-ipsc-therapy-for-cardiovascular-disease 2025-04-16T13:32:57+00:00 hourly 0.9 https://trial.medpath.com/news/octave-s-msda-test-transforms-ms-care-with-biomarker-driven-insights 2025-04-16T11:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/octave-s-msda-test-transforms-ms-care-with-biomarker-driven-insights 2025-04-16T11:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-ct-132-first-digital-therapeutic-for-episodic-migraine-prevention 2025-04-16T10:33:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-ct-132-first-digital-therapeutic-for-episodic-migraine-prevention 2025-04-16T10:33:32+00:00 hourly 0.9 https://trial.medpath.com/news/datchat-secures-european-patent-allowance-for-advanced-digital-privacy-technology 2025-04-16T08:40:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/datchat-secures-european-patent-allowance-for-advanced-digital-privacy-technology 2025-04-16T08:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/thirtyfivebio-secures-bridge-financing-to-advance-novel-gpr35-inhibitor-for-ulcerative-colitis-treatment 2025-04-16T08:33:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thirtyfivebio-secures-bridge-financing-to-advance-novel-gpr35-inhibitor-for-ulcerative-colitis-treatment 2025-04-16T08:33:14+00:00 hourly 0.9 https://trial.medpath.com/news/naya-therapeutics-regains-independence-to-advance-first-in-class-cancer-immunotherapies-with-2025-2026-clinical-milestones 2025-04-16T08:33:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/naya-therapeutics-regains-independence-to-advance-first-in-class-cancer-immunotherapies-with-2025-2026-clinical-milestones 2025-04-16T08:33:08+00:00 hourly 0.9 https://trial.medpath.com/news/autonomix-medical-secures-european-patent-for-neuromodulation-technology-targeting-cancer-pain 2025-04-16T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/autonomix-medical-secures-european-patent-for-neuromodulation-technology-targeting-cancer-pain 2025-04-16T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/new-heart-failure-treatment-protocol-reduces-mortality-by-nearly-two-thirds-in-uk-hospitals 2025-04-16T08:08:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-heart-failure-treatment-protocol-reduces-mortality-by-nearly-two-thirds-in-uk-hospitals 2025-04-16T08:08:20+00:00 hourly 0.9 https://trial.medpath.com/news/luma-vision-s-verafeye-4d-cardiac-imaging-system-receives-fda-clearance 2025-04-16T08:07:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/luma-vision-s-verafeye-4d-cardiac-imaging-system-receives-fda-clearance 2025-04-16T08:07:52+00:00 hourly 0.9 https://trial.medpath.com/news/fda-authorizes-breakthrough-tango-belt-device-that-reduces-hip-fractures-by-91-in-older-adults 2025-04-16T06:03:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-authorizes-breakthrough-tango-belt-device-that-reduces-hip-fractures-by-91-in-older-adults 2025-04-16T06:03:33+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-ceribell-s-ai-algorithm-for-pediatric-seizure-detection-in-patients-as-young-as-one-year-old 2025-04-16T05:32:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-ceribell-s-ai-algorithm-for-pediatric-seizure-detection-in-patients-as-young-as-one-year-old 2025-04-16T05:32:56+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-abeona-s-novel-cell-therapy-for-rare-skin-disease 2025-04-16T05:32:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-abeona-s-novel-cell-therapy-for-rare-skin-disease 2025-04-16T05:32:55+00:00 hourly 0.9 https://trial.medpath.com/news/ziresovir-shows-breakthrough-efficacy-against-rsv-in-infants-under-6-months-with-long-term-benefits 2025-04-16T05:03:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ziresovir-shows-breakthrough-efficacy-against-rsv-in-infants-under-6-months-with-long-term-benefits 2025-04-16T05:03:17+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-prescient-s-ptx-100-for-cutaneous-t-cell-lymphoma-treatment 2025-04-16T05:03:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-prescient-s-ptx-100-for-cutaneous-t-cell-lymphoma-treatment 2025-04-16T05:03:13+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-biologics-secures-settlement-with-regeneron-to-launch-aflibercept-biosimilar-in-us-by-2026 2025-04-16T05:03:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocon-biologics-secures-settlement-with-regeneron-to-launch-aflibercept-biosimilar-in-us-by-2026 2025-04-16T05:03:06+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-evidence-validates-proenkephalin-a-119-159-as-superior-kidney-function-biomarker-in-critical-care 2025-04-16T04:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-evidence-validates-proenkephalin-a-119-159-as-superior-kidney-function-biomarker-in-critical-care 2025-04-16T04:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/tevogen-bio-partners-with-databricks-to-advance-ai-driven-immunotherapy-target-prediction-platform 2025-04-16T02:04:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tevogen-bio-partners-with-databricks-to-advance-ai-driven-immunotherapy-target-prediction-platform 2025-04-16T02:04:22+00:00 hourly 0.9 https://trial.medpath.com/news/adar1-gene-identified-as-key-driver-of-lenalidomide-resistance-in-multiple-myeloma 2025-04-16T02:04:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adar1-gene-identified-as-key-driver-of-lenalidomide-resistance-in-multiple-myeloma 2025-04-16T02:04:11+00:00 hourly 0.9 https://trial.medpath.com/news/dm-clinical-research-partners-with-florida-sleep-specialists-to-advance-obesity-and-sleep-disorder-treatments 2025-04-16T02:04:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dm-clinical-research-partners-with-florida-sleep-specialists-to-advance-obesity-and-sleep-disorder-treatments 2025-04-16T02:04:10+00:00 hourly 0.9 https://trial.medpath.com/news/scipher-medicine-and-kythera-labs-form-strategic-partnership-to-advance-precision-medicine-in-rheumatology 2025-04-16T01:34:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scipher-medicine-and-kythera-labs-form-strategic-partnership-to-advance-precision-medicine-in-rheumatology 2025-04-16T01:34:11+00:00 hourly 0.9 https://trial.medpath.com/news/turing-medical-appoints-kevin-king-as-ceo-to-advance-brain-mapping-technology-and-depression-treatment 2025-04-16T00:05:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/turing-medical-appoints-kevin-king-as-ceo-to-advance-brain-mapping-technology-and-depression-treatment 2025-04-16T00:05:14+00:00 hourly 0.9 https://trial.medpath.com/news/abu-dhabi-s-m42-invests-in-juvenescence-to-advance-ai-driven-longevity-research 2025-04-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abu-dhabi-s-m42-invests-in-juvenescence-to-advance-ai-driven-longevity-research 2025-04-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-lenmeldy-4-25-million-gene-therapy-for-rare-childhood-disease-mld 2025-04-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-lenmeldy-4-25-million-gene-therapy-for-rare-childhood-disease-mld 2025-04-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bluerock-therapeutics-reports-promising-18-month-data-from-phase-1-parkinson-s-cell-therapy-trial-in-nature-publication 2025-04-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bluerock-therapeutics-reports-promising-18-month-data-from-phase-1-parkinson-s-cell-therapy-trial-in-nature-publication 2025-04-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/neonc-technologies-strengthens-competitive-edge-with-176-patent-global-portfolio 2025-04-15T23:33:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neonc-technologies-strengthens-competitive-edge-with-176-patent-global-portfolio 2025-04-15T23:33:30+00:00 hourly 0.9 https://trial.medpath.com/news/boehringer-ingelheim-and-cue-biopharma-partner-on-novel-b-cell-targeting-therapy-for-autoimmune-diseases 2025-04-15T23:32:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boehringer-ingelheim-and-cue-biopharma-partner-on-novel-b-cell-targeting-therapy-for-autoimmune-diseases 2025-04-15T23:32:54+00:00 hourly 0.9 https://trial.medpath.com/news/repurposed-blood-pressure-drug-shows-promise-for-treating-inherited-retinal-diseases-with-sex-specific-benefits 2025-04-15T23:04:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/repurposed-blood-pressure-drug-shows-promise-for-treating-inherited-retinal-diseases-with-sex-specific-benefits 2025-04-15T23:04:35+00:00 hourly 0.9 https://trial.medpath.com/news/metavia-s-novel-dual-receptor-agonist-shows-promising-6-3-weight-loss-in-phase-1-obesity-trial 2025-04-15T23:03:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metavia-s-novel-dual-receptor-agonist-shows-promising-6-3-weight-loss-in-phase-1-obesity-trial 2025-04-15T23:03:47+00:00 hourly 0.9 https://trial.medpath.com/news/qiagen-to-launch-three-new-sample-preparation-instruments-by-2026-expanding-lab-automation-capabilities 2025-04-15T22:33:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qiagen-to-launch-three-new-sample-preparation-instruments-by-2026-expanding-lab-automation-capabilities 2025-04-15T22:33:11+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-rmat-designation-to-iltamiocel-for-post-cancer-treatment-dysphagia 2025-04-15T20:33:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-rmat-designation-to-iltamiocel-for-post-cancer-treatment-dysphagia 2025-04-15T20:33:32+00:00 hourly 0.9 https://trial.medpath.com/news/galmed-discovers-novel-blood-biomarkers-for-aramchol-expanding-therapeutic-potential-beyond-mash 2025-04-15T20:33:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galmed-discovers-novel-blood-biomarkers-for-aramchol-expanding-therapeutic-potential-beyond-mash 2025-04-15T20:33:24+00:00 hourly 0.9 https://trial.medpath.com/news/illumina-and-tempus-join-forces-to-advance-precision-medicine-through-ai-powered-genomics 2025-04-15T20:04:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/illumina-and-tempus-join-forces-to-advance-precision-medicine-through-ai-powered-genomics 2025-04-15T20:04:59+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-rmat-designation-to-lyell-s-dual-targeting-car-t-cell-therapy-lyl314-for-relapsed-refractory-lbcl 2025-04-15T20:04:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-rmat-designation-to-lyell-s-dual-targeting-car-t-cell-therapy-lyl314-for-relapsed-refractory-lbcl 2025-04-15T20:04:22+00:00 hourly 0.9 https://trial.medpath.com/news/ssc-ild-market-projected-to-reach-750-million-by-2034-as-novel-therapies-enter-pipeline 2025-04-15T20:04:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ssc-ild-market-projected-to-reach-750-million-by-2034-as-novel-therapies-enter-pipeline 2025-04-15T20:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-ind-for-genetically-engineered-porcine-liver-system-to-treat-acute-on-chronic-liver-failure 2025-04-15T20:04:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-ind-for-genetically-engineered-porcine-liver-system-to-treat-acute-on-chronic-liver-failure 2025-04-15T20:04:06+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-xellsmart-s-ipsc-derived-cell-therapies-for-parkinson-s-disease-and-als-clinical-trials 2025-04-15T18:05:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-xellsmart-s-ipsc-derived-cell-therapies-for-parkinson-s-disease-and-als-clinical-trials 2025-04-15T18:05:40+00:00 hourly 0.9 https://trial.medpath.com/news/neuphoria-advances-dual-clinical-programs-with-merck-partnership-milestone-and-phase-3-sad-trial-progress 2025-04-15T17:34:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuphoria-advances-dual-clinical-programs-with-merck-partnership-milestone-and-phase-3-sad-trial-progress 2025-04-15T17:34:46+00:00 hourly 0.9 https://trial.medpath.com/news/abu-dhabi-launches-multi-partner-initiative-to-advance-precision-medicine-and-genomic-healthcare 2025-04-15T17:34:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abu-dhabi-launches-multi-partner-initiative-to-advance-precision-medicine-and-genomic-healthcare 2025-04-15T17:34:38+00:00 hourly 0.9 https://trial.medpath.com/news/spruce-biosciences-acquires-tralesinidase-alfa-for-sanfilippo-syndrome-type-b-treatment-with-bla-submission-planned-for-2026 2025-04-15T17:33:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spruce-biosciences-acquires-tralesinidase-alfa-for-sanfilippo-syndrome-type-b-treatment-with-bla-submission-planned-for-2026 2025-04-15T17:33:56+00:00 hourly 0.9 https://trial.medpath.com/news/dyne-therapeutics-strengthens-leadership-team-with-key-scientific-and-business-appointments 2025-04-15T17:33:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dyne-therapeutics-strengthens-leadership-team-with-key-scientific-and-business-appointments 2025-04-15T17:33:54+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-terumo-neuro-s-first-in-class-dual-layer-micromesh-carotid-stent-system 2025-04-15T17:33:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-terumo-neuro-s-first-in-class-dual-layer-micromesh-carotid-stent-system 2025-04-15T17:33:50+00:00 hourly 0.9 https://trial.medpath.com/news/rege-nephro-acquires-tamibarotene-assets-from-syros-pharmaceuticals-for-adpkd-development 2025-04-15T17:33:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rege-nephro-acquires-tamibarotene-assets-from-syros-pharmaceuticals-for-adpkd-development 2025-04-15T17:33:49+00:00 hourly 0.9 https://trial.medpath.com/news/mytomorrows-and-scout-clinical-launch-partnership-to-revolutionize-cross-border-clinical-trial-recruitment 2025-04-15T17:33:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mytomorrows-and-scout-clinical-launch-partnership-to-revolutionize-cross-border-clinical-trial-recruitment 2025-04-15T17:33:15+00:00 hourly 0.9 https://trial.medpath.com/news/novavax-covid-19-vaccine-shows-fewer-side-effects-than-pfizer-biontech-in-shield-utah-study 2025-04-15T15:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novavax-covid-19-vaccine-shows-fewer-side-effects-than-pfizer-biontech-in-shield-utah-study 2025-04-15T15:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-and-novo-nordisk-alert-consumers-to-counterfeit-ozempic-in-u-s-market 2025-04-15T15:05:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-and-novo-nordisk-alert-consumers-to-counterfeit-ozempic-in-u-s-market 2025-04-15T15:05:19+00:00 hourly 0.9 https://trial.medpath.com/news/uae-partnership-to-slash-car-t-cancer-therapy-costs-by-90-through-local-manufacturing 2025-04-15T14:40:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uae-partnership-to-slash-car-t-cancer-therapy-costs-by-90-through-local-manufacturing 2025-04-15T14:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/new-sustained-release-flucytosine-enters-phase-ii-trials-for-cryptococcal-meningitis-amid-hiv-funding-crisis 2025-04-15T14:03:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-sustained-release-flucytosine-enters-phase-ii-trials-for-cryptococcal-meningitis-amid-hiv-funding-crisis 2025-04-15T14:03:19+00:00 hourly 0.9 https://trial.medpath.com/news/nimacimab-tirzepatide-combination-achieves-over-30-weight-loss-in-preclinical-obesity-study 2025-04-15T14:03:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nimacimab-tirzepatide-combination-achieves-over-30-weight-loss-in-preclinical-obesity-study 2025-04-15T14:03:14+00:00 hourly 0.9 https://trial.medpath.com/news/baylink-biosciences-to-present-novel-adc-platform-data-for-cancer-treatment-at-aacr-2025 2025-04-15T14:03:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/baylink-biosciences-to-present-novel-adc-platform-data-for-cancer-treatment-at-aacr-2025 2025-04-15T14:03:13+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-gene-editing-advances-car-nk-cell-therapy-to-overcome-clinical-bottlenecks 2025-04-15T14:03:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crispr-gene-editing-advances-car-nk-cell-therapy-to-overcome-clinical-bottlenecks 2025-04-15T14:03:09+00:00 hourly 0.9 https://trial.medpath.com/news/genmab-reports-strong-q1-2025-darzalex-sales-of-3-24-billion-demonstrating-continued-market-dominance 2025-04-15T13:43:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genmab-reports-strong-q1-2025-darzalex-sales-of-3-24-billion-demonstrating-continued-market-dominance 2025-04-15T13:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/third-harmonic-bio-stockholders-approve-liquidation-plan-as-thb335-shows-85-tryptase-reduction-in-phase-1-trial 2025-04-15T12:03:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/third-harmonic-bio-stockholders-approve-liquidation-plan-as-thb335-shows-85-tryptase-reduction-in-phase-1-trial 2025-04-15T12:03:04+00:00 hourly 0.9 https://trial.medpath.com/news/norgine-expands-rare-disease-portfolio-with-strategic-acquisition-of-theravia 2025-04-15T11:33:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/norgine-expands-rare-disease-portfolio-with-strategic-acquisition-of-theravia 2025-04-15T11:33:34+00:00 hourly 0.9 https://trial.medpath.com/news/coherus-biosciences-completes-558-4-million-udenyca-divestiture-to-intas-pivots-to-oncology-focus 2025-04-15T11:33:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/coherus-biosciences-completes-558-4-million-udenyca-divestiture-to-intas-pivots-to-oncology-focus 2025-04-15T11:33:02+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-advances-respiratory-pipeline-with-promising-amlitelimab-data-in-heterogeneous-inflammatory-asthma 2025-04-15T11:03:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-advances-respiratory-pipeline-with-promising-amlitelimab-data-in-heterogeneous-inflammatory-asthma 2025-04-15T11:03:05+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-corxel-s-phase-ii-trial-for-oral-glp-1-receptor-agonist-cx11-in-obesity-treatment 2025-04-15T09:05:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-corxel-s-phase-ii-trial-for-oral-glp-1-receptor-agonist-cx11-in-obesity-treatment 2025-04-15T09:05:04+00:00 hourly 0.9 https://trial.medpath.com/news/evommune-s-mrgprx2-antagonist-evo756-shows-promise-in-chronic-urticaria-trials 2025-04-15T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evommune-s-mrgprx2-antagonist-evo756-shows-promise-in-chronic-urticaria-trials 2025-04-15T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/geovax-advances-multi-antigen-covid-19-vaccine-and-expands-oncology-pipeline-despite-barda-setback 2025-04-15T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/geovax-advances-multi-antigen-covid-19-vaccine-and-expands-oncology-pipeline-despite-barda-setback 2025-04-15T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/vascarta-launches-first-human-trial-of-transdermal-curcumin-therapy-for-sickle-cell-disease 2025-04-15T08:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vascarta-launches-first-human-trial-of-transdermal-curcumin-therapy-for-sickle-cell-disease 2025-04-15T08:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/fluidform-bio-achieves-breakthrough-in-vascularized-tissue-engineering-for-diabetes-treatment 2025-04-15T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fluidform-bio-achieves-breakthrough-in-vascularized-tissue-engineering-for-diabetes-treatment 2025-04-15T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/imperative-care-launches-first-randomized-trial-of-aspiration-thrombectomy-for-m2-stroke-occlusions 2025-04-15T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imperative-care-launches-first-randomized-trial-of-aspiration-thrombectomy-for-m2-stroke-occlusions 2025-04-15T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/galapagos-cfo-and-coo-thad-huston-to-depart-as-company-advances-cell-therapy-transformation 2025-04-15T06:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galapagos-cfo-and-coo-thad-huston-to-depart-as-company-advances-cell-therapy-transformation 2025-04-15T06:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/heparegenix-secures-eur21-5-million-to-advance-novel-liver-regeneration-therapy 2025-04-15T05:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/heparegenix-secures-eur21-5-million-to-advance-novel-liver-regeneration-therapy 2025-04-15T05:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-in-colorectal-cancer-drug-discovery-novel-nano-delivery-systems-and-precision-therapy-targets-identified 2025-04-15T01:33:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-in-colorectal-cancer-drug-discovery-novel-nano-delivery-systems-and-precision-therapy-targets-identified 2025-04-15T01:33:08+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-lupus-nephritis-treatment-gsk-s-benlysta-autoinjector-for-pediatric-patients 2025-04-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-lupus-nephritis-treatment-gsk-s-benlysta-autoinjector-for-pediatric-patients 2025-04-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/tvardi-therapeutics-completes-merger-with-cara-advances-stat3-inhibitor-programs-for-fibrosis-driven-diseases 2025-04-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tvardi-therapeutics-completes-merger-with-cara-advances-stat3-inhibitor-programs-for-fibrosis-driven-diseases 2025-04-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ripretinib-demonstrates-efficacy-as-neoadjuvant-therapy-for-gist-in-first-case-report 2025-04-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ripretinib-demonstrates-efficacy-as-neoadjuvant-therapy-for-gist-in-first-case-report 2025-04-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/j-j-raises-2025-sales-forecast-despite-400m-tariff-impact-following-intra-cellular-acquisition 2025-04-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/j-j-raises-2025-sales-forecast-despite-400m-tariff-impact-following-intra-cellular-acquisition 2025-04-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/chromatin-bioscience-and-astellas-partner-to-develop-cell-selective-synthetic-promoters-for-precision-gene-expression 2025-04-14T21:03:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chromatin-bioscience-and-astellas-partner-to-develop-cell-selective-synthetic-promoters-for-precision-gene-expression 2025-04-14T21:03:32+00:00 hourly 0.9 https://trial.medpath.com/news/edwards-lifesciences-secures-first-ce-mark-for-transfemoral-mitral-valve-replacement-system 2025-04-14T21:03:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/edwards-lifesciences-secures-first-ce-mark-for-transfemoral-mitral-valve-replacement-system 2025-04-14T21:03:15+00:00 hourly 0.9 https://trial.medpath.com/news/scancell-partners-with-nhs-to-fast-track-promising-cancer-vaccine-trial 2025-04-14T21:03:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scancell-partners-with-nhs-to-fast-track-promising-cancer-vaccine-trial 2025-04-14T21:03:13+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-conditional-approval-for-carmat-s-aeson-artificial-heart-second-cohort-study 2025-04-14T20:02:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-conditional-approval-for-carmat-s-aeson-artificial-heart-second-cohort-study 2025-04-14T20:02:54+00:00 hourly 0.9 https://trial.medpath.com/news/sohum-health-launches-nih-funded-clinical-trial-comparing-buprenorphine-formulations-for-rural-opioid-use-disorder-treatment 2025-04-14T18:09:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sohum-health-launches-nih-funded-clinical-trial-comparing-buprenorphine-formulations-for-rural-opioid-use-disorder-treatment 2025-04-14T18:09:38+00:00 hourly 0.9 https://trial.medpath.com/news/ab-science-secures-us-patent-for-masitinib-in-sickle-cell-disease-treatment-until-2040 2025-04-14T18:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ab-science-secures-us-patent-for-masitinib-in-sickle-cell-disease-treatment-until-2040 2025-04-14T18:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/certara-launches-non-animal-navigator-solution-to-reduce-animal-testing-in-drug-development 2025-04-14T17:35:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/certara-launches-non-animal-navigator-solution-to-reduce-animal-testing-in-drug-development 2025-04-14T17:35:15+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-warning-for-zoetis-canine-osteoarthritis-drug-librela-after-reports-of-serious-adverse-reactions 2025-04-14T17:35:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-warning-for-zoetis-canine-osteoarthritis-drug-librela-after-reports-of-serious-adverse-reactions 2025-04-14T17:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/precision-medicine-biologics-poised-to-transform-30-2-billion-copd-market-by-2033 2025-04-14T17:10:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precision-medicine-biologics-poised-to-transform-30-2-billion-copd-market-by-2033 2025-04-14T17:10:50+00:00 hourly 0.9 https://trial.medpath.com/news/inmune-bio-partners-with-cgt-catapult-to-scale-cordstrom-manufacturing-for-rare-skin-disease-treatment 2025-04-14T17:09:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inmune-bio-partners-with-cgt-catapult-to-scale-cordstrom-manufacturing-for-rare-skin-disease-treatment 2025-04-14T17:09:39+00:00 hourly 0.9 https://trial.medpath.com/news/ironwood-pharmaceuticals-faces-setback-as-fda-requires-additional-phase-3-trial-for-apraglutide 2025-04-14T17:09:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ironwood-pharmaceuticals-faces-setback-as-fda-requires-additional-phase-3-trial-for-apraglutide 2025-04-14T17:09:36+00:00 hourly 0.9 https://trial.medpath.com/news/reveal-genomics-and-ona-therapeutics-partner-to-advance-novel-adc-cancer-treatment-with-biomarker-strategy 2025-04-14T17:09:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/reveal-genomics-and-ona-therapeutics-partner-to-advance-novel-adc-cancer-treatment-with-biomarker-strategy 2025-04-14T17:09:04+00:00 hourly 0.9 https://trial.medpath.com/news/jama-oncology-study-confirms-oncotype-dx-test-effectiveness-across-all-racial-and-ethnic-groups 2025-04-14T17:07:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jama-oncology-study-confirms-oncotype-dx-test-effectiveness-across-all-racial-and-ethnic-groups 2025-04-14T17:07:28+00:00 hourly 0.9 https://trial.medpath.com/news/pheast-therapeutics-initiates-phase-1-trial-of-novel-anti-cd24-macrophage-checkpoint-inhibitor-for-advanced-solid-tumors 2025-04-14T17:07:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pheast-therapeutics-initiates-phase-1-trial-of-novel-anti-cd24-macrophage-checkpoint-inhibitor-for-advanced-solid-tumors 2025-04-14T17:07:26+00:00 hourly 0.9 https://trial.medpath.com/news/ironwood-pharmaceuticals-faces-setback-in-apraglutide-development-for-short-bowel-syndrome 2025-04-14T14:35:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ironwood-pharmaceuticals-faces-setback-in-apraglutide-development-for-short-bowel-syndrome 2025-04-14T14:35:17+00:00 hourly 0.9 https://trial.medpath.com/news/scancell-and-nhs-partner-to-accelerate-melanoma-vaccine-trial-recruitment 2025-04-14T14:35:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scancell-and-nhs-partner-to-accelerate-melanoma-vaccine-trial-recruitment 2025-04-14T14:35:08+00:00 hourly 0.9 https://trial.medpath.com/news/can-fite-biopharma-secures-3-million-in-funding-to-advance-clinical-trials-for-oncology-and-inflammatory-disease-treatments 2025-04-14T14:28:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/can-fite-biopharma-secures-3-million-in-funding-to-advance-clinical-trials-for-oncology-and-inflammatory-disease-treatments 2025-04-14T14:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/synact-pharma-launches-phase-ii-trial-of-resomelagon-for-dengue-treatment-in-brazil 2025-04-14T14:04:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/synact-pharma-launches-phase-ii-trial-of-resomelagon-for-dengue-treatment-in-brazil 2025-04-14T14:04:58+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-bruno-vision-care-s-revolutionary-deseyne-contact-lenses-with-controlled-release-hydration-technology 2025-04-14T14:04:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-bruno-vision-care-s-revolutionary-deseyne-contact-lenses-with-controlled-release-hydration-technology 2025-04-14T14:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/lobe-sciences-secures-6m-private-placement-for-novel-conjugated-psilocin-development-in-chronic-cluster-headache 2025-04-14T14:04:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lobe-sciences-secures-6m-private-placement-for-novel-conjugated-psilocin-development-in-chronic-cluster-headache 2025-04-14T14:04:13+00:00 hourly 0.9 https://trial.medpath.com/news/cspc-pharmaceutical-s-sys6041-and-syh2046-receive-fda-approval-for-clinical-trials 2025-04-14T14:04:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cspc-pharmaceutical-s-sys6041-and-syh2046-receive-fda-approval-for-clinical-trials 2025-04-14T14:04:06+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-cellenkos-ck0801-for-aplastic-anemia-treatment 2025-04-14T14:04:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-cellenkos-ck0801-for-aplastic-anemia-treatment 2025-04-14T14:04:01+00:00 hourly 0.9 https://trial.medpath.com/news/ainos-advances-veldona-oral-interferon-platform-with-dual-clinical-trial-approvals-for-rare-diseases 2025-04-14T14:02:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ainos-advances-veldona-oral-interferon-platform-with-dual-clinical-trial-approvals-for-rare-diseases 2025-04-14T14:02:52+00:00 hourly 0.9 https://trial.medpath.com/news/once-weekly-insulin-icodec-combined-with-cgm-shows-promising-results-for-type-2-diabetes-management 2025-04-14T13:41:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/once-weekly-insulin-icodec-combined-with-cgm-shows-promising-results-for-type-2-diabetes-management 2025-04-14T13:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/elix-and-prism-biolab-partner-to-revolutionize-drug-discovery-for-protein-protein-interaction-targets 2025-04-14T11:05:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elix-and-prism-biolab-partner-to-revolutionize-drug-discovery-for-protein-protein-interaction-targets 2025-04-14T11:05:49+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-bms-s-opdivo-yervoy-combination-for-first-line-treatment-of-advanced-liver-cancer 2025-04-14T11:05:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-bms-s-opdivo-yervoy-combination-for-first-line-treatment-of-advanced-liver-cancer 2025-04-14T11:05:38+00:00 hourly 0.9 https://trial.medpath.com/news/dea-under-fire-for-seven-year-delay-in-medical-marijuana-research-application 2025-04-14T11:05:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dea-under-fire-for-seven-year-delay-in-medical-marijuana-research-application 2025-04-14T11:05:06+00:00 hourly 0.9 https://trial.medpath.com/news/sandoz-files-antitrust-lawsuit-against-amgen-to-unlock-access-to-etanercept-biosimilar-in-us-market 2025-04-14T07:33:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sandoz-files-antitrust-lawsuit-against-amgen-to-unlock-access-to-etanercept-biosimilar-in-us-market 2025-04-14T07:33:52+00:00 hourly 0.9 https://trial.medpath.com/news/sun-pharma-s-leqselvi-advances-toward-launch-after-favorable-us-court-ruling 2025-04-14T07:33:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sun-pharma-s-leqselvi-advances-toward-launch-after-favorable-us-court-ruling 2025-04-14T07:33:12+00:00 hourly 0.9